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ABSTRACT 
Objectives. To explore medical decision-making capacity (MDC) for research participation, 
in patients with Alzheimer's disease, using a linguistic approach and including comparable 
groups. 
Materials and Methods. The thesis comprises five studies, based upon two separate data 
collections from three groups of elderly with varied cognitive function: Alzheimer’ disease 
(AD; dataset 1: n= 20 and dataset II: n=21), mild cognitive impairment (MCI; dataset 1: n= 
22 and dataset II: n=17) and healthy controls (HC; dataset 1: n= 37 and dataset II: n=17). 
Studies I-III and V are primarily quantitative studies investigating medical decision-making 
in research as measured by two different linguistic instruments (LIMD and KIMB) and 
patients’ self-estimation by visual analogue scale (VAS), correlated to demographic factors 
and cognitive and linguistic abilities. Study IV is a qualitative study, analysing the sense-
making of selected utterances by conducting semantic analysis.  
Results. Study I: A Swedish Linguistic Instrument of Medical-Decision making (LIMD) was 
developed and demonstrated good psychometric features. Study II: Multiple factors are 
involved in MDC (assessed by LIMD) such as overall verbal knowledge, episodic memory, 
cognitive speed and working memory. LIMD total score showed highest correlation to the 
single test Reading Speed (which assesses both rapid reading, inference and understanding). 
Study III: AD patients showed high acceptance to participate in a high-risk trial as well as 
reduced capability to notify risk. Study IV: Irregularly placed, and sporadically used linguistic 
signs for time, place and person may lead to difficulties interpreting and understanding the 
meaning of verbal utterances. Study V: A brief Swedish reading tool (KIMB-t) was developed 
to detect patients with reduced capacity to give informed consent.  
Conclusions. The linguistic and cognitive functions associated with comprehending, 
evaluating and communicating a choice, may affect MDC, referred to as the capacity to make 
decisions in research settings e.g. to give informed consent. Patients, already with mild AD 
are likely to have reduced capacity to identify and estimate possible risks as well as 
difficulties in reasoning and to communicate a choice in a clear and logical manner. 
Evaluating different aspects associated to medical decision-making from a linguistic 
perspective, in groups with varied cognitive function, contributes to further knowledge in the 
field. The results indicate that a linguistic approach can contribute not only to further analysis 
of MDC, but also to a better understanding in the communication with patients with impaired 




Syfte. Undersöka medicinsk beslutsförmåga, definierad som förmågan att fatta beslut vid 
forskning t.ex. ge informerat samtycke, utifrån ett språkligt perspektiv, hos patienter med 
lindrig Alzheimers sjukdom, och jämförande grupper.  
Material och metoder. Avhandlingen omfattar totalt fem delstudier och är baserad på två 
separata datainsamlingar som inkluderar tre grupper av äldre med varierad kognitiv funktion: 
Patienter med lindrig Alzheimersjukdom (AD; datainsamling I: n = 20; och datainsamling II: 
n = 21), Lindrig kognitiv störning (MCI; datainsamling I: n = 22 och datainsamling II: n = 
17) och friska kontroller (HC; datainsamling I: n = 37 och datainsamling II: n = 17). Studie 
I-III och V är huvudsakligen kvantitativa studier som undersöker beslutsförmåga och 
resonemang mha olika mätinstrument, korrelerade med demografiska faktorer samt kognitiva 
och språkliga test. Studie IV redovisas som en kvalitativ studie, vilken analyserar 
begripligheten i utvalda verbala resonemang mha semantisk analys. 
Resultat. Studie I: Ett svenskt lingvistiskt test av medicinsk beslutsförmåga, LIMD har 
utvecklats med goda psykometriska egenskaper. Studie II: Flera faktorer är involverade i 
medicinsk beslutsförmåga (mätt med LIMD) t.ex. verbal kunskap, episodminne, snabbhet 
och arbetsminne. LIMDs totalpoäng visade starkast samband den enskilda uppgiften: 
”Läshastighet”, som mäter både läshastighet och förståelse av text. Studie III: AD patienter 
förefaller ha hög acceptans att delta i hög-riskstudier samt reducerad förmåga att skatta risk. 
Studie IV: Avvikande och sporadiskt använda språkliga markörer för tid, plats och person 
kan leda till svårigheter att tolka och förstå begripligheten i verbala uttalanden. Studie V: En 
kort svensk läsuppgift (KIMB-t) har utvecklats för att upptäcka patienter med risk för 
reducerad förmåga att ge informerat samtycke. 
Slutsatser. Språkliga och kognitiva förmågor associerade till att förstå, utvärdera och att 
kommunicera ett val, kan påverka förmågan att fatta beslut vid forskning, t.ex. ge informerat 
samtycke som är baseras på skriven information. Redan vid lindrig AD kan patienter riskera 
att ha en påverkad beslutsförmåga. De förefaller också ha nedsatt förmåga att identifiera och 
uppskatta eventuella risker och att motivera och kommunicera ett beslut på ett tydligt och 
logiskt sätt. Resultaten indikerar att ett språkligt perspektiv kan bidra, inte bara till analys av 
MDC, men också till bättre förståelse i kommunikationen med patienter med nedsatt kognitiv 
funktion, under beslutsprocessen. 
  
PROLOGUE 
I have always had a genuine interest in the human mind and communication. During previous 
work in elderly home care, I developed a certain interest in the elderly as a vulnerable group, 
enriched with experiences and knowledge from the past. Unfortunately, some have 
difficulties communicating their stories and their desires due to language disorders, memory 
loss or other cognitive impairments caused by neurodegenerative diseases. In addition, the 
interlocutor may have more or less capability (e.g. time or interest) to capture and interpret 
the meaning of their utterances. My experience in elderly care made me curious to learn more 
about the brain and communication, which lead me into the study of speech and language 
pathology and my current employment at Karolinska University Hospital, Stockholm. 
 
In my clinical work as a speech and language pathologist, I had the opportunity to be involved 
in a major research network; Swedish Brain Power, where numerous researchers worked 
together to improve the situation of patients with neurodegenerative diseases. My entrance 
into the network was to explore issues concerning medical decision-making. The linguistic 
perspective of medical decision-making, originated from the discipline of speech and 
language pathology, formed the base of my PhD-project. Nevertheless, an interdisciplinary 
approach is necessary in order to fully explore the complexity of decision-making. I have 
attempted to merge different perspectives throughout my studies and for this effort I am most 
grateful for the collaboration with my supervisors, co-authors and colleagues, who 
contributed with their extensive knowledge in speech and language pathology, 
neuropsychology, medicine, linguistics, and ethics.  
 
Evaluating the decision-making procedure and the capacity is about identifying various signs, 
more or less visible or audible. I am convinced that an interdisciplinary collaboration and 
discussion can improve and facilitate the decision-making procedures, for the exposed and 
fragile group of patients with neurodegenerative diseases. I am most grateful to have been 
part of past and ongoing interdisciplinary discussions which have empowered both my 
research in medical decision-making and clinical work, evaluating language and 
communication disorders among patients with impaired cognitive function.  
  
  
LIST OF SCIENTIFIC PAPERS 
The thesis includes five studies as shown below. The studies are referred to in the text by 
their Roman numeral. Reprints of studies I, II and III, were made with permission from the 
publisher.  
 
I. Tallberg I.M., Stormoen S., Almkvist, O., Eriksdotter-Jönhagen M. & Sundström, E. 
(2013). Investigating medical decision-making capacity in patients with cognitive 
impairment using a protocol based on linguistic features. Scandinavian Journal of 
Psychology, 54(5): 386-92. doi.org/10.1111./sjop.12068. 
 
II. Stormoen S., Almkvist, O., Eriksdotter, M. & Sundström, E., & Tallberg I.M. (2014). 
Cognitive predictors of medical decision-making capacity in mild cognitive impairment 
and Alzheimer’s disease. International Journal of Geriatric Psychiatry, 29(12), 1304-
1311. doi: 10.1002/gps.4114. 
 
III. Stormoen S., Almkvist, O., Eriksdotter, M., Sundström E. & Tallberg I.M. (2017). 
Decisions and attitudes regarding participation and proxy in clinical trials among patients 
with impaired cognitive function. Dementia, doi: 10.1177/1471301217737413. [Epub 
ahead of print] 
 
IV. Stormoen, S. & Tallberg, IM. Semantic analysis of sense-making in a hypothetical clinical 
trial. Manuscript. 
 
V. Stormoen, S.*, Thalén, L.*, Almkvist O., Eriksdotter M.,  Heimann Mühlenbock, K., 
Sundström E. & Tallberg I.M. * equal contribution. Validation of a brief test to detect 
impairment in medical decision-making capacity. Manuscript. 
CONTENTS 
1 Background ............................................................................................................... 2 
1.1 Informed consent ......................................................................................................... 2 
1.2 Medical decision-making capacity .............................................................................. 3 
1.2.1 Associated cognitive and linguistic functions ............................................................. 5 
1.2.2 Neuroanatomical correlates ....................................................................................... 6 
1.2.3 Assessments .............................................................................................................. 6 
1.3 Dementia .................................................................................................................... 10 
1.4 Alzheimer’s Disease ................................................................................................... 10 
1.5 Mild Cognitive Impairment ...................................................................................... 12 
1.6 Decision-making characteristics in impaired cognitive function ............................. 12 
1.7 Ethical issues.............................................................................................................. 13 
1.8 Aims of the project .................................................................................................... 14 
2 Methods ................................................................................................................... 15 
2.1 Procedures ................................................................................................................. 15 
2.2 Participants ................................................................................................................ 16 
2.2.1 Study I .................................................................................................................... 17 
2.2.2 Study II ................................................................................................................... 17 
2.2.3 Study III .................................................................................................................. 17 
2.2.4 Study IV ................................................................................................................. 17 
2.2.5 Study V ................................................................................................................... 17 
2.3 Material and assessments .......................................................................................... 18 
2.3.1 Study I .................................................................................................................... 19 
2.3.2 Study II ................................................................................................................... 24 
2.3.3 Study III .................................................................................................................. 24 
2.3.4 Study IV ................................................................................................................. 25 
2.3.5 Study V ................................................................................................................... 27 
2.4 Statistical analysis...................................................................................................... 29 
2.5 Ethical considerations ............................................................................................... 32 
3 Results ...................................................................................................................... 33 
3.1 Study I........................................................................................................................ 33 
3.1.1 Scoring ................................................................................................................... 33 
3.1.2 Reliability ............................................................................................................... 33 
3.1.3 Validity ................................................................................................................... 33 
3.2 Study II ...................................................................................................................... 34 
3.2.1 Scoring ................................................................................................................... 34 
3.2.2 LIMD versus cognitive and linguistic tests .............................................................. 34 
3.3 Study III..................................................................................................................... 35 
3.3.1 Acceptance to participate......................................................................................... 35 
3.3.2 Reasons for participation ......................................................................................... 36 
3.3.3 Estimations of risk and benefit ................................................................................ 37 
3.3.4 Attitude toward proxy ............................................................................................. 37 
3.4 Study IV ..................................................................................................................... 38 
3.5 Study V ...................................................................................................................... 39 
3.5.1 KIMB-t ................................................................................................................... 39 
3.6 In sum ........................................................................................................................ 40 
4 Discussion ................................................................................................................ 41 
4.1 Methodological topics ................................................................................................ 41 
4.1.1 Procedure ................................................................................................................ 41 
4.1.2 Participants ............................................................................................................. 42 
4.1.3 Material and Assessments ....................................................................................... 44 
4.1.4 Statistics .................................................................................................................. 45 
4.2 The linguistic approach ............................................................................................. 46 
  
4.3 LIMD and KIMB-t .................................................................................................... 49 
4.3.1 Diagnostic validity .................................................................................................. 50 
4.3.2 Construct validity .................................................................................................... 51 
4.3.3 Ecological validity .................................................................................................. 55 
4.3.4 Usefulness ............................................................................................................... 56 
4.4 Ethical issues.............................................................................................................. 56 
5 Conclusions .............................................................................................................. 60 
6 Future directions ..................................................................................................... 61 
7 Acknowledgements .................................................................................................. 62 




AD Alzheimer’s disease 
ADRDA The Alzheimer’s Disease and Related Disorders Association   
ANOVA Analysis of variance 
BeSS Assessment of subtle language disorders (bedömning av subtila 
språkstörningar) 
BNT Boston Naming Test 
C Controls 
CCTI The Capacity to Consent to Treatment Instrument 
DLS Assesments of reading and writing function (diagnostiskt material för analys 
av läs- och skrivförmåga) 
ES Erik Sundström 
FAS Phonemic verbal fluency test: FAS (letters: f, a, s)  
FTD Frontotemporal dementia 
HC Healthy Controls 
HCP Health care proxy 
HD Huntington disease 
HDM Health care decision-making 
ICD-10 The International Statistical Classification of Diseases and Related Health 
Problems, a medical classification list by the World Health Organization. 
IMT Ing-Mari Tallberg 
KHM Katarina Heimann Mühlenbock 
KIMB Kliniskt Instrument för Medicinsk Beslutsförmåga 
KIMB-q KIMB questionnaire 
KIMB-t KIMB target word task 
LIMD  The Swedish Linguistic Instrument of Medical Decision-making Linguistic  
LS Legal Standards 
LT Liv Thalén 
MacCAT-CR MacArthur Competence Assessment Tool for Clinical Research 
MACCAT-T MacArthur Competence Assessment Tool for Treatment 
MANOVA Multivariate analysis of variance 
MCI Mild Cognitive Impairment 
MDC Medical decision-making capacity (referred to in current PhD-project as 
capacity in research context) 
  
MDMC Medical decision-making capacity (referred to in current PhD-project as 
capacity in research context) 
ME Mia Eriksdotter 
MMSE The Mini Mental State Examination 
MoCA The Montreal Cognitive Assessment 
NIA The National Institute on Aging 
NIA-AA  The Alzheimer's Association published revised guidelines 
NIH National Institute of Health 
NINCDS The National Institute of Neurological and Communicative Disorders and 
Stroke 
OA Ove Almkvist 
PD Parkinson’s disease 
Q Question, referred to as questions in LIMD or KIMB. 
R-O Rey-Osterrieth test (copy and retention) 
RAVL Rey Auditory Verbal Learning Test 
RAVLT  Rey Auditory Verbal Learning Test Total learning 
S standards (e.g. standards for consent) 
SS Sara Stormoen 
STROOP Stroop Color and Word Test 
TCC Treatment consent capacity 
TL Test leader 
TMT Trail Making Test (A and B) 
UBACC The University of California Brief Assessment of Capacity to Consent 
VAS Visual analogue scales (0-100mm) used in study IV to estimate e.g. 
risk/benefit. 
WAIS-R Wechsler Adult Intelligence Scale Revised 
WMA  World Medical Association

  1 
INTRODUCTION 
 “Everything we see hides another thing, we always want to see what is hidden by what we see. 
There is an interest in that which is hidden and which the visible does not show us. This interest 
can take the form of a quite intense feeling, a sort of conflict, one might say, between the visible 
that is hidden and the visible that is present” Rene Magritte (1965), about his painting: Le 
fils de l'homme. 
 
Reasoning and decisions may not always be communicated clearly and concisely. Sometimes 
the true sense of an utterance may be difficult to interpret and the extent of a person’s 
capability to make an autonomous decision may be in question. Comprehension, reasoning and 
ability to communicate a choice may be reduced or lacking completely due to several causes, 
for example the cognitive decline caused by a neurodegenerative disease such as Alzheimer’s. 
Several studies have investigated the medical decision-making procedure from a 
neuropsychological perspective and it is well-recognized that numerous of cognitive functions 
are correlated to the decisional capacity. It has been reported that language and communication 
abilities have impact on decisional capacity, although the linguistic perspective seems to have 
earned less attention within the field. The discipline of speech and language pathology formed 
the theoretical foundation of the thesis, from which an interface between neuropsychology and 
medical ethics was created and constituted an exploratory approach to the study of medical 
decision-making capacity (MDC) in research settings such as to give informed consent. The 
overall aim of the PhD-project was to explore medical decision-making in patients with 
Alzheimer’s disease, by use of a linguistic approach.   
 
Three key assumptions formed the starting point for the studies: (1) patients with Alzheimer’s 
disease have to some extent reduced capacity to comprehend, evaluate and communicate a 
choice as well as reason in a logical manner; (2) linguistic abilities are central in order to obtain 
informed consent and (3) exploring the decision making from a linguistic perspective in AD in 
comparison to groups with varied cognitive function, may add further knowledge to field of 
MDC. Notable, the studies included in the current thesis, are referring to MDC as the capacity 
to make decisions for research, such as the ability to give informed consent. Yet, the capacity 
is described and discussed also from other reference points in the theoretical background of the 
thesis and in respectively study. 
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1 BACKGROUND 
Medical-decision making capacity and associated elements have been widely discussed in the 
last decades among researchers from different disciplines (e.g. medical ethics and 
neuropsychology). Following sections in the background are reporting some previous findings, 
disagreements and consensus of different aspects of medical decision-making, that are 
considered central for the PhD-project (but the thesis does not aim to review the overall 
intradisciplinary debate of medical decision-making in neither research or treatment settings).  
1.1 INFORMED CONSENT  
Informed consent can be described as an individual’s valid authorisation or refusal of a 
medical intervention. Informed consent serves to protect patients’ autonomy, as the consent 
refers not only to being informed but in addition also to voluntary and competent. In other 
words, medical and research settings should provide the patient with adequate information, so 
that the patient can make an authentic decision. The Declaration of Helsinki is a key set of 
guidelines for medical ethics adopted by the 18th World Medical Association (WMA) General 
Assembly in Helsinki, Finland in June, 1964 and revised repeatedly since. The Declaration has 
had impact on medical ethic and national legalisation for example concerning informed consent. 
One of its fundamental principles is that concern for the individual is superior to the interests 
of science and society (World Medical Association, Declaration of Helsinki, 2013).  
 
It has been suggested that informed consent to research should contain some fundamental 
elements concerning information, voluntarism and capacity to make a decision such as (1) 
ensure safety, (2) allow the patient or potential subject to be autonomous, (3) entail information 
of the total procedure as well as (4) report potential benefits and risks. A common difference 
between consent procedures for research in comparison to treatment is that participants 
enrolling a clinical trial need to understand the difference between possible interventions within 
the research project such as placebo as well as the terms and conditions of the research protocol 
(e.g. Appelbaum & Roth. 1982; Roberts, 2002; Gupta & Kharawala, 2012). 
 
The term health literacy, has strengthened the individual perspective of inherit control of own 
health, such as for example the importance of making an autonomous decision (Nutbeam, 
2008). Ringsberg, Olander and Tillgren (2017) discussed healthy literacy and emphasized that 
individuals have different conditions to take independent responsibility for their own health and 
Sarvimäki and Stenbock-Hult (2017) implied that elderly may risk to face challenges in health 
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literacy, as cognitive impairment is associated with several age-related diseases. Furthermore, 
Montalvo and Larson (2014) implied that there is an overall inconsistency in the degree of 
health literacy among research participants, meaning for example that the participant could face 
difficulties in capturing given key information concerning for example placebo, benefit and 
risk. Charles, Lidz, Appelbaum, Grisso, and Renaud (2004) implied that patients may risk to 
have only modest ability to appreciate the given risks when signing a consent to participate in 
a clinical trial. The authors imply that insufficient ability to identify and differentiate the 
consequences described in a research protocol undermines the informed consent procedure. 
1.2 MEDICAL DECISION-MAKING CAPACITY 
Palmer and Harmell (2016) implied in a recent paper, that consensus on a clear and overall 
definition concerning the capacity of healthcare decision-making seems difficult to reach. 
Intradisciplinary discussions of medical decision-making capacity have struggled with for 
example ethical issues, applicability in law, definition of the capacity and critical standards as 
well as its associated cognitive functions and neuroanatomic correlates. In addition, the 
decision-making capacity has in previous literature been referred to by different definitions and 
abbreviations. Yet, it is worth noting, that competence or incompetence is a legal term and is, 
if needed, the outcome of a formal legal procedure. 
 
In the 80's, Appelbaum and Grisso (1988), among others, have discussed certain functional 
abilities, central for decision-making: (1) communicating a choice, (2) understanding relevant 
information, (3) appreciating current situation and its consequences and (4) manipulating 
information rationally. These have been referred to as e.g. standards for competence and are 
well established in the overall field of decision-making but have also been the target for 
discussion throughout the years. One general discussion concern that the model is mostly 
“cognitive”, not attending to other issues, such as patient values and emotions, that could affect 
the capacity.  
 
Another topic of discussion has concerned to include and merge standards into fewer or 
different categories. The functional standards understanding, reasoning and appreciation have 
been discussed and problematised in several previous studies (e.g. Marson, Cody, Ingram & 
Harrell, 1995 and Moye, Karel, Gurrera and Azar, 2006). Okonkwo et al. (2008), among others, 
explored medical decision-making capacity by including an experimental standard “making a 
reasonable choice” when evaluating the ability to communicate a choice as a consent capacity. 
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Yet, the authors pointed out that this additional standard is not generally accepted, as the degree 
of “reasonable” in a choice is difficult to measure in an objective and standardized manner, i.e. 
making a reasonable choice may be associated with appreciation and a reflection of the 
information to one's self and one's own situation. In addition, the reasonableness in utterances 
may sometimes be ambiguous or unexpected due to for example personal attitude and ethical 
considerations. Also, Grisso and Appelbaum (1998) were discussing the standard “expressing 
a choice”, emphasizing a clear and consistent choice, since individuals may be able to 
communicate but unable to choose.  
 
Further on, “the understanding” standard has been problematized by for example Dunn and 
Jeste (2001) underscored the difficulty of knowing what the measurement of “understanding” 
actually is referring to. Functions like comprehension, knowledge, and recall have been used to 
describe the “understanding” standard. Another aspect is the issue of what abilities the 
participant needs to require to truly comprehend the context of given research protocol. The 
authors underscored that neither knowledge nor recall do necessary imply understanding. 
Buckles et al. (2003) were investigated decision-making capacity for research participation 
among patients with mild to moderate AD, by an exploratory approach: only evaluating one 
dimension of the capacity: “understanding” (i.e. capacity to comprehend consent information 
in a relatively simply research protocol). Yet, they found, in line with previous studies that the 
patients showed reduced capacity. The authors implied that the capacity to provide rational 
reasons for choice or to actually understand the given context may presumable be more 
cognitive demanding in comparison to for example the standards: “communicate a decision” or 
“appreciating the consequences of participation”. 
 
An additional angle to the discussion was raised in a recent study, which explored psychiatrists’ 
judgements and interpretation of decision-making. They reported that decisional capacity can 
be considered not only depending on previously well-established standards, but also to the 
actual choice. The authors implied that patients who made irrational decisions were considered 
to be “irresponsible” for the listener, although they were perhaps yet capable of making a 
decision (Sjöstrand, Karlsson, Sandman, Helgesson, Eriksson & Juth, 2015). 
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1.2.1 Associated cognitive and linguistic functions  
In decision-making, a certain level of cognitive and linguistic function is needed, in order to 
acquire information to identify, understand and evaluate different options, and to finally 
communicate a choice. Several previous studies have reported certain cognitive characteristics 
as being associated with the different standards and dimensions of decisional-making capacity 
(assessed by different instruments and among different groups). Gurrera, Moye, Karel, Azar, & 
Armesto (2006) emphasized that verbal retrieval, among others, is an important cognitive 
correlate to decision-making capacity among patients with mild to moderate dementia. 
Furthermore, Gurrera, Karel, Azar and Moye (2014) underscored that the overall capacity to 
make a decision depends on numerous of interactions between different cognitive functions, 
rather than on any single function alone. Cognitive models based on performance in tests of 
executive function, semantic memory and delayed recall could serve to examine aspects of 
decisional capacity. Nevertheless, performance in cognitive tasks can serve to predict decisional 
capacity only to some extent. Several previous studies (e.g. Gerstenecker et al., 2015; Grisso & 
Appelbaum, 1998; Dunn & Jeste, 2001) have showed that verbal function is associated to the 
decision-making capacity.  
 
Palmer and Savla (2007) underscored certain central abilities associated with the cognitive 
process of consent capacity, such as short-term memory (e.g. encode information for further 
processing), language comprehension (e.g. understand information), conceptualization and 
executive function (e.g. processing of information), judgment and reasoning (rational 
evaluating and weighting information), expressive language (e.g. communicating a choice). It 
was also reported that the ability to understand (as a component of decision-making in research) 
may be associated to several elements such as (1) knowledge of a participation in the study, (2) 
ability to remember information as well as (3) a general understanding of the meaning of 
randomization procedures (e.g. placebo treatments). Furthermore, Palmer and Harmell (2016) 
reported association between certain neurocognitive domains and healthcare decision-making, 
such as episodic memory, naming, working memory, executive functions and speed. The 
authors also summarised previously findings of what cognitive abilities appear to be correlated 
to different components of decision-making capacity:  
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• The ‘understanding’ component –executive function (Dymek, Atchison, Harrell, &  
Marson, 2001), processing speed, episodic memory (Okonkwo et al., 2008a), verbal 
function, fluency and memory (Gerstenecker et al., 2015).  
• The ‘appreciation’ component –working memory (Palmer, Dunn, Appelbaum & 
Jeste, 2004), episodic memory and mental speed (Okonkwo et al., 2008a). 
• The ‘reasoning’ component –working memory (Palmer et al., 2004), executive 
function (Dymek et al., 2001; Marson, Chatterjee, Ingram, and Harrell, 1996), episodic 
memory and expressive language function (Okonkwo et al., 2007). 
1.2.2 Neuroanatomical correlates 
Medical decision-making capacity is complex and depends, as we have seen, on several 
cognitive and linguistics functions. Consequently, the capacity cannot be associated with only 
one isolated part of the brain but can rather be considered as a result of several neurological 
processes. Despite this complexity, researchers have tried to localise and describe the key 
neurological systems involved in decision-making. For example, Kable and Glimcher (2009), 
identified two basic stages in the neurobiological mechanism for choice: (1) The 
multicomponent valuation, which is suggested to be associated with the prefrontal cortex and 
parts of the striatum, and (2) The choice, associated with activity in the lateral prefrontal and 
parietal areas. Hsu, Bhatt, Adolphs, Tranel and Camerer (2005) suggested that activity in the 
prefrontal cortex is associated with random choices, commonly noted among individuals 
with AD. Gleichgerrcht, Ibanez, Roca, Torralva & Manes (2010) reviewed neuroanatomical 
patterns of decision-making among those with neurodegenerative diseases (AD, frontotemporal 
dementia, FTD, Parkinson’s disease, PD and Huntington’s disease, HD).  Three central 
neurological systems for decision-making were identified: (1) A stimulus encoding system, 
associated with the orbitofrontal and ventromedial prefrontal cortex, (2) An action selection 
system, related to the anterior cingulate cortex and the lateral prefrontal and parietal cortices 
and (3) An expected reward system, associated with basal ganglia, amygdala and insula. 
1.2.3 Assessments 
Researchers seem to agree upon that the capacity to make a valid decision is not static but 
changeable, due to both individual factors (e.g. patient’s status) and contextual factors (e.g. the 
complexity of decision-making situation and time restrictions) (e.g. Palmer & Harmell, 2016). 
Hence, sufficient or insufficient capacity must always be assessed on an individual basis. Braun, 
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Gurrera, Karel, Armesto and Moye (2009) investigated whether clinicians are biased in their 
conclusions on the decision-making capacity of elderly patients. They reported that 
unstructured determinations of the capacity may be problematic, as even the most skilled 
medical professionals may find it difficult to determine the capacity. Unstructured estimations 
may lead to disagreements as well as questionable validity and inter-rater reliability. They 
reported also that the estimations were associated to the clinicians’ idea of how the patient was 
involved in decisions such as for example emotional reactions. Sessum, Zembrzuska and 
Jackson, (2011), were also reporting difficulties among physicians to recognize decision-
making incapacity in patients determined (through more formal assessments) insufficient to 
make health care decisions. The authors emphasized the use of standardized measurement tools, 
based on predefined key criteria when estimating medical decision-making capacity. 
Pennington, Davey, Ter Meulen, Coulthard and Kehoe (2018) emphasize that several 
approaches e.g. individual and cultural perspective as well as medical status must be considered 
when estimating decision-making capacity in dementia. The authors also pointed out that it 
does not exist any gold standard for capacity instruments, which stress the importance for both 
clinicians and researchers to apply different approaches when evaluating the capacity. Finally, 
Buckles et al., (2003) implied that brief tools to evaluate if patients understand the context of a 
research protocol would be beneficial to apply when enrolling patients with dementia in a 
consent process.  
1.2.3.1 Tests 
Estimation of cognitive severity by for example Mini Mental State Examination (MMSE; 
Folstein, Folstein & McHugh, 1975) or Montreal Cognitive Assessment (MoCA; Nasreddine 
et al., 2005), can serve to give an initial assumption of the patient’s cognitive status. Yet, 
specific valid tests are acquired to evaluate decision-making capacity. Several instruments have 
been developed and validated to examine different dimensions of the capacity and should 
preferable be used when the capacity needs to be examined in detail. Several reviews have 
reported assessments tools of decision-making capacity in different health care and research 
settings. Notable, objectives, design, administration, scoring procedures, validity and 
usefulness differ among the assessment tools (for details see for example reviews and papers 
by Karlawish, 2017; Palmer and Harmell, 2016; Lamont, Jeon & Chiarella, 2013; Pennington 
et al., 2018). Some well-established instruments to assess different aspects of the capacity are: 
the MacArthur Competence Assessment Tool for Treatment (MacCAT-T), the MacArthur 
Competence Assessment Tool for Clinical Research (MacCAT-CR) (Grisso, Appelbaum and 
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Hill-Fotouhi, 1997; Grisso and Appelbaum, 1998, Appelbaum and Grisso, 2001), the Capacity 
to Consent to Treatment Instrument (CCTI) (Marson, Ingram, Cody & Harrell, 1995a) and the 
University of California Brief Assessment of Capacity to Consent (UBACC) (Jeste et al., 
2007). Most instruments can be divided into two general test designs: “decision-at-hand” and 
“vignettes”, described in short below (Palmer and Harmell, 2016): 
 
• Decision-at-hand. Some instruments are designed to assess the capacity tailored to the 
decision at hand (i.e. current, real information). These assessments often consist of 
structured or semi-structured interview formats based on the current situation (for 
example decisions concerning a certain treatment or other health care issues) in addition 
to scoring guidelines. Since the responses are specific to the situation at hand, the 
assessment procedure and questions must be adjusted to the explored situations. This 
can cause difficulties with standardisation, reliability and validity. Dunn, Nowrangi, 
Palmer, jeste & Saks (2006) noted that the contextual impact needs to be further 
investigated and that tools of this type need to undergo further research. 
 
• Vignettes. The so-called vignette-method is a common approach, which assesses the 
decisional capacity based on hypothetical situations. As these instruments by their 
nature include fictional information, for example concerning a certain disease and/or 
clinical trial, the method is generalisable among both situations and patients, but also 
requires a certain level of ability in figurative thinking and hypothetical reasoning. A 
possible concern is uncertainty about whether the participants would make the same 
choice in a real situation. 
1.2.3.2 Linguistic analysis 
Semantics and pragmatics are concerned with the study of meaning, such as for example how 
linguistic signs in the speech (e.g. words) are associated with meaning. Johansson and 
Manninen (2012) proposed that “the meaning of meaning” can be studied from a referential 
perspective (i.e. meaning is derived from the link between linguistic signs and objects that exist 
or might exist in the real world) or from a mental perspective (i.e. assuming that a word has a 
meaning because it activates a concept in the mind of the speaker/listener). The authors also 
discuss different kinds of meaning: linguistic versus encyclopaedic, literal versus associative 
and literal versus non-literal meaning. The study of meaning is of interest not only for linguistic 
semantics, but also studied among philosophers, psychologists and computational scientists.  
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Examining the linguistic signs for person, place and time in the speech adds further knowledge 
about the meaning of the utterances. Time can be expressed by verbal tense or by time 
adverbials (e.g. then, now). Place relates to the speaker’s perception of his/her position in 
space/room (e.g. here, there). Person may concern the speaker (e.g. personal pronouns such as 
I, you, he or she). Signs of misperception and confabulations in patients’ speech can be 
explained as a disturbance of her/his self- image in relation to time and space. For example, the 
pronoun ‘I’ may risk losing its actual meaning (e.g. whom it is referring to) if it is presented as 
a self without a connection to time and place (Tallberg, 1999). 
 
An interview is a complex process during in which the interviewer and responder may display 
various clear or subtle linguistic and communication features. Clark and Schaefer (1989) 
proposed a theoretical linguistic model to help identify whether successful exchange of 
information has occurred in the decision-making conversation. This model structures a 
hierarchy of evidence of understanding and can contribute to an overall assessment of decision-
making capacity. The model was modified in a recent study by Brauner and Merel (2006) as 
the “Modified Hierarchy of Evidence of Decision-Making Capacity” and includes well-defined 
core features such as: (1) Continued attention, (2) Acknowledgment (backchanneling, for 
example, nodding, saying “yeah” or “uh-huh” and (3) Next relevant contribution; (3a) single 
word answers (yes, no, maybe etc.), (3b) single word answers plus confirmatory language (yes, 
I think so), (3c) paraphrases, (3d) new idea (that signals understanding of previous 
contribution). Brauner and Merel conducted a linguistic analysis based on the modified model, 
of semi-structured interviews concerning different hypothetical research texts, as well as the 
four previously defined functional abilities (Appelbaum & Grisso, 1988). Brauner and Merel 
(2006) explored these functional standards by their linguistic model summarized as followed:  
 
• Communicateing a choice  - e.g. continued attention, eye contact, acknowledgement: 
back channelling. 
• Understanding information related to the options – e.g. paraphrasing,  anaphora, 
need for repair, response to repair.  
• Appreciating the context, including its consequences – e.g. reference to one´s 
disease,  “Aha” contribution.  
• Reasoning about the information rationally – e.g. recognisable reason. 
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The model also considered that confusing language can be a sign of questionable decisional 
capacity. Yet, thoughtful actions by the interviewer, such as successfully “repairing” confused 
language in the interaction, can result in the participant being able to improve their capability 
to answer the questions. 
1.3 DEMENTIA 
The term "dementia" does not constitute a disease in itself, but rather a set of symptoms whereby 
an acquired cognitive impairment significantly affects functional ability and declines over time. 
Cognitive failure may occur in a variety of conditions and diseases. Even at high age, cognitive 
ability may be affected by other more common diseases where the combination of high age and 
multiple illness may lead to significant cognitive impairment. In order for the criteria for 
dementia to be met, the cognition should have declined over time, during more than six months, 
and must be pronounced and lowered in comparison to previous level as well as affect work or 
social life. Dementia is more common among the elderly, prevalence > 65 years has been 
reported as 8% in Swedish population. Around 160 000 people have dementia in Sweden today 
(24 000 newly diagnosed persons per year). It is not possible to cure dementia, but the health 
and social services can contribute to facilitate everyday life and contribute to quality of life in 
the various stages of the disease. The National Board of Health recommends an 
interprofessional approach to provide best possible efforts in dementia care (Guidelines for 
Dementia; The National Board of Health, Rev. 2017).  
1.4 ALZHEIMER’S DISEASE 
Alzheimer’s disease (AD) is the leading cause of dementia, accounting for 50–70% of cases. 
The primary risk factor for AD is of age (Winblad et al., 2016). The clinical diagnosis of AD in 
Sweden is defined according to the ICD-10 classification. AD is recognized by for example (1) 
impaired function in multiple cognitive domains: memory impairment is obligatory, as well as 
any other interference such as aphasia, apraxia, agnosia or impaired executive function; (2) the 
impairments lead to a significant decline in social or occupational functions and (3) the course 
is characterised by a gradual onset and continuous deterioration. Both in the clinic and in 
research often the National Institute of Neurological and Communicative Disorders and Stroke 
(NINCDS) and the Alzheimer´s Disease and Related Disorders Association (ADRDA) criteria 
from 1984 have been used, but the criteria was recently updated by the National Institute on 
Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease 
NIA-AA criteria (McKhann et al. 2011), including new categories such as proof of the AD 
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pathophysiological process using biomarkers of AD pathophysiology reflecting amyloid b-
deposition and neurodegeneration. However, due to the need of standardisation and availability 
of quantitative analytical techniques, the use of biomarkers is still not recommended in the 
clinical setting, but often included in the diagnostic process when available. There is increasing 
evidence to show that AD starts many years before symptoms occur (Winblad et al., 2016). 
 
Typical examples of communication deficits in AD is an inadequate ability to follow the 
"thread" of conversation. Furthermore, morphological, syntactic and lexical discrepancies of 
language function and general vocabulary difficulties have been observed. Reading capacity is 
also commonly impaired in AD, such as reduced ability identifying and reading out the words, 
decoding texts and to actually processing and comprehend the content, which requires 
additional cognitive functions such as semantic and episodic memory. In addition, the impaired 
reading function in AD could be reduced due to a disturbed visual processing (e.g. Emery & 
Olga, 2000; Glossera, et al., 2002; Fernandéz, Schumacher, Casstro, Orozco & Agamennoni, 
2015; Obler and Gjerlow, 1999). In a study by Tallberg and Almkvist (2001), it was noted that 
impaired cognitive function in AD can be related to an increased number of confabulations. 
The authors highlighted the relevance of listening to what may be perceived as irrelevant speech 
and attempting to understand what the person with AD is trying to convey. Automated verbal 
pronouncements and the syntactic structure can be relatively well-maintained far into the 
disease development. When cognitive, communicative and pragmatic functions are disturbed, 
it usually means a need for a specially adapted environment (Penn, 1999). Impaired language 
functions, such as the ability to recall words, may be noted even in the early stages of the gradual 
cognitive degeneration of AD and when the disease progresses the ability to express and 
comprehend language decreases (Bayles, Tomoeda, Cruz & Mahendra, 2000). Furthermore, de 
Lira, Ortiz, Camanha, Bertolucci and Minett (2011) explored fluctuations in the speech of AD 
patients and found that both lexical and syntactic performance were lower than expected. 
Individuals with AD may be relatively adept at finding strategies to conceal their difficulties, 
thus possibly giving a distorted picture of their functional ability. For example, they may have 
sustained the capacity to read as an automatic process, although comprehension of the text is 
reduced or completely lacking (Emery, 2000).  
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1.5 MILD COGNITIVE IMPAIRMENT 
Mild cognitive impairment (MCI), refers to the clinical state of a minor impairment in cognitive 
function, typically memory, but with normal performance in other domains and not meeting the 
criteria for clinically probable AD. Some patients with MCI show amnestic MCI characterized 
by memory loss, with a high rate (10-15%) of progression to AD, in comparison to healthy 
elderly (converting at a rate of 1-2% per year). However, there are multiple sources of 
heterogeneity in MCI as some patients may develop AD, while others may progress to other 
dementia diagnoses, or never progress to a significant extent (Winblad et al, 2004).  
1.6 DECISION-MAKING CHARACTERISTICS IN IMPAIRED COGNITIVE 
FUNCTION 
Palmer and Harmell (2016) implied that cognitive impairment seems to be highly associated 
with impaired health care decision-making capacity, also including patients with other 
dominant symptoms. Age-related diseases involving cognitive impairment may impact 
decision-making capacity (Petersen et al., 2007; Mata, Schooler & Rieskamp, 2007) and it is 
well-recognised that reduced decision-making capacity can be found in patients with various 
neurodegenerative diseases. In a study by Okonkwo et al. (2008b), people with cognitive 
impairments were found to have significantly lower ability to evaluate, reason and understand 
compared to healthy controls and impaired decisional capacity has been noted even in mild AD 
(Gurrera et al., 2006). Jefferson et al., (2008) used the Maccat-CR to examined decisional-
capacity for research participation among patients with MCI. Their results indicated, in line 
with previously findings, that also patients with MCI show impaired decision-making capacity. 
In addition, the patients who failed to provide informed consent for a hypothetical clinical trial, 
which they were exposed to in the exploratory study, were less educated. However, the 
characteristics of decision-making deficit vary between diagnoses and change over time, as the 
cognitive impairment progressively worsens (Buckles et al., 2003; Gleichgerrcht et al., 2010). 
A different communication style such as “a silently agreeing manner” for research participation 
has been identified among patients with dementia (Sugarman et al. 2007), which may risk to be 
falsely interpreted as for example a willingness to participate. The authors imply that, not only 
the cognitive status of the patient, but in addition social and emotional considerations should 
be considered in the discussion concerning proxy and consent in dementia. 
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1.7 ETHICAL ISSUES 
A debated issue in dementia research concerns obtaining informed consent from patients with 
impaired cognitive function (e.g. Peterson and Wallin, 2003; Slaughter, Cole, Jennings, & 
Reimer, 2007). Critical ethical issues associated with medical decision-making concern for 
example patient autonomy. Autonomy is a loaded word and considered as a fundamental human 
right, in Sweden as well as in numerous of other countries (see e.g. World Medical Association, 
Declaration of Helsinki, 2013). Determination of sufficient or insufficient decision-making 
capacity may lead to ethical and medical consequences for the patient. One ethical issue is the 
important responsibility of finding the right balance between autonomy for individuals as well 
as protections for those with reduced capacity to make autonomous decisions (Berghmans & 
Widdershoven, 2003). Furthermore, Johansson (2017) underscores the importance of being 
sensitive to what the patients communicates, even when decisional capacity is considered 
insufficient, i.e. not to listen to individuals, whatever their identity or status is to adopt an 
attitude towards the other as an object rather than a subject, which is not consistent with good 
medical ethics. Proxy consent may be needed if certain decisional capacity is considered 
insufficient (e.g. White & Seery, 2009). Dubois et al. (2011) underscored that attitude toward 
proxy seem to vary in relation to the potential risk associated to the situation, such as for 
example it seems to be a higher willingness to accept proxy regarding possible engagement to 
low-risk research. This stress the importance of discussing patient’s attitude and choice of proxy 
preferably before the decisional capacity is significantly reduced. Furthermore, Moye, Sabatino 
and Weintraub et al (2013) emphasize the importance of exploring possible similarities and 
differences between different type of capacity, such as to consent to treatment or to appoint a 
future proxy and Kim, Caine, Currier, Leibovici and Ryan (2001) were reported that patients 
with questionable decision-making capacity may to some extent have sufficient capacity to 
appoint a proxy to make decisions on their behalf. Smebye, Kirkevold and Engedal, (2012) 
point out that families are essentially already in the initial phase of a dementia disease, to pursue 
shared or supported decision-making, e.g. facilitate information and guide through different 
options, but leave the final decision to the patient. Swedish law states that researchers must 
apply for permission from regional ethical vetting board for any research that affects a human 
being. A Swedish act of Future Proxy came into force, to allow to designate a future proxy. The 
powers and selection criteria of a future proxy can be in general or specified to certain situations 
(https://www.riksdagen.se/sv/dokument-lagar/dokument/svensk-forfattningssamling/lag-
2017310-om-framtidsfullmakter_sfs-2017-310). 
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1.8 AIMS OF THE PROJECT 
The overall objective of the PhD-project was to explore various aspects of medical decision-
making for research involving patients with mild AD, by applying a linguistic perspective and 
include comparable groups of interest. The different objectives of each study are summarised 
below:  
 
I. To develop and validate a Swedish linguistic instrument of medical decision-making 
capacity for research, among groups of patients with Alzheimer’s disease (AD) and mild 
cognitive impairment (MCI) and comparable healthy elderly individuals (HC). 
II. To examine the association between cognition and MDC in research (by LIMD) using 
a comprehensive battery of cognitive and linguistic tests 
III. To evaluate how groups with various cognitive functions (AD, MCI and HC) reason 
and estimate risks and benefits in the context of possible participation in hypothetical 
clinical trials. 
IV. To explore the meaning of utterances concerning a hypothetical clinical trial by 
conducting semantic analysis of time, person and place. 
V. To develop and validate a Swedish brief task to detect compromised informed consent 
to research among patients with AD. 
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2 METHODS 
2.1 PROCEDURES 
Medical decision-making capacity in the PhD-project is abbreviated as MDC or MDMC, which 
is referring to the capacity to make decisions for research, such as the ability to give informed 
consent. Yet, results from previous research referring to other definitions and aspects of the 
capacity are reported and discussed to some extent within the thesis and in respectively study 
(I-V).  
 
The studies are derived from two separate data collections: data collection I (studies I-IV), data 
collection II (study V). Each participant was only participating in one of the two data 
collections. 
 
The first collection (studies I-IV) was conducted between 2009-2010 (by SS). Data collection 
one contained in addition to the new instrument LIMD a large test battery including 
neuropsychological and linguistic tests and VAS. The total test procedure was durable 
approximately 3-4 hours per participant (including breaks). The data was analysed by several 
evaluators (IMT, OA and SS). 
 
The second data collection (study V) was conducted between 2015-17 (by SS and LT) and by 
students of speech and language pathology (RH and EL). Data collection two contained in 
addition to the new tool KIMB some cognitive and linguistic tests and was durable 
approximately 1.5 hours per participant. The data was analysed by two evaluators (SS and LT).  
 
In addition to the test design of LIMD and KIMB, a large number of scientific methods were 
applied in order to analyse the data in studies I-V such as (1) assessment of cognitive and 
linguistic tests, (2) structured interviewing (regarding three hypothetical clinical trials as part 
of LIMD) (3) orthographical transcription of audio recorded speech, (4) standardised scoring 
of verbal responses by LIMD protocol, (5) blinded analysis of test results, (6) manually 
measuring participants self-estimations by VAS, (7) statistical analyses, (8) semantic analyses 
of transcribed speech. The test design of LIMD and KIMB was settled before initiating the data 
collections to enable a standardized assessment and scoring procedure.  
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The results emanated from two scientific approaches: (1) quantitative (study I-III and V), by 
reporting the scores of neuropsychological and linguistic tests as wells as the scores by different 
measurements of MDC and self-estimations by VAS and (2) qualitative (study IV), by semantic 
analysis of the speech. The qualitative approach in study IV aim to contribute to a deeper 
understanding of the speech and can be viewed upon as an extension of study I-III as theses 
four studies report from the same data collection (I). 
2.2 PARTICIPANTS 
The two data collections included different individuals but groups with similar diagnostic 
clinical features (enrolled by similar inclusion and exclusion criteria): (1) Patients with mild 
Alzheimer’s disease (AD) and (2) Mild Cognitive Impairment (MCI) as well as an age matched 
group of (3) Healthy individuals (HC). 
 
All patients (AD and MCI) were recruited from the Karolinska University Hospital memory 
clinic. The diagnosis of AD followed NINCDS-ADRDA criteria (McKhann, Drachman, 
Folstein, Katzman, Price & Stadlan, 1984) and ICD-10, while diagnoses of MCI followed 
clinical criteria including subjective cognitive complaints, objective verification of cognitive 
impairment and maintained activities of daily living (Winblad et al., 2004). The inclusion 
criteria from the clinical investigation at the Memory clinical were for the patients the patients 
(MMSE: AD>20) and those with a mild cognitive impairment (MCI) (MMSE: MCI>25), 
(Folstein et al., 1975), Cornell Scale for Depression in dementia ≤9 (Alexopoulos, Abrams, 
Young & Shanoian, 1988) and diagnosed within the last 12 months.  
 
HC were recruited through spouses to patients, extended networks and advertisements in public 
areas e.g. library, churches and hospitals. The main inclusion criteria for the HC group was 
absence of depression or other psychiatric condition, neurological disease, dementia or other 
diagnosis that could affect language or cognitive ability. Additional inclusion criteria for all 
three groups (AD, MCI and HC) were: (1) Swedish as (one or one of several) first language(s), 
(2) no reported dyslexia and (3) no substantial hearing or visual impairment which cannot be 
corrected by aids. 
 
Demographic characteristics were reported at group level: studies I-III (age, gender and 
education) and study V (age and education). Study IV did not include and compare 
demographic characteristics but included data (transcribed verbal utterances) from data 
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collection I. Overall cognitive severity was an inclusion criterion (MMSE ≥20) as investigated 
as part of the clinical examination but was also re-tested as part of the two data collections (by 
MMSE in data collection I and by MoCA in data collection II) and it was the score from the 
data collections, which was used in the analyses.  
2.2.1 Study I 
Data collection I: Three groups: (1) patients with dementia of the Alzheimer type (AD, n=20), 
(2) patients with mild cognitive impairment (MCI, n=22), and (3) healthy controls (HC, n=37). 
Groups differed significantly (p<.001) in overall cognitive function by the Mini-Mental Status 
Examination (MMSE; Folstein et al., 1975): AD: 24.1±3.3, MCI: 26.7±2.4 and HC: 29.1±1.0). 
No significant group effects (all p>.10) for demographic features (gender, age and education). 
2.2.2 Study II 
Three groups were selected from data collection I: (1) patients with dementia of the Alzheimer 
type (AD, n=20), (2) patients with mild cognitive impairment (MCI, n=21) and (3) healthy 
controls (HC, n=33). Significant groups differences (p <.001) by the Mini-Mental Status 
Examination (MMSE; Folstein et al., 1975; AD: 24.1±3.6, MCI: 26.6±2.4 and HC: 29.1±1.0). 
No significant group effects (all p>.10) for demographic features (gender, age and education). 
2.2.3 Study III 
The same three groups as in Study II (see above, section 2.2.2)  
2.2.4 Study IV 
The analysis includes responses from four participants (AD, n=2 and HC, n=2), taken from data 
collection I. Note, the result does not reveal the total sum of utterances from one individual but 
presents a mixture of responses (taken from the LIMD-interview) from the four selected 
individuals, and the utterances were reported by the two groups (AD and HC).  
2.2.5 Study V 
Data collection II: Three groups: (1) patients with dementia of the Alzheimer type (AD, n=21), 
(2) patients with mild cognitive impairment (MCI, n=17) and (3) healthy controls (HC, n=17) 
from data collection II.  Groups differed significantly in overall cognitive severity as measured 
by The Montreal Cognitive Assessment Battery (MoCA; Nasreddine et al., 2005; p <.001; AD: 
19.72±3.37, MCI: 24.00±2.15 and HC: 26.88±2.13) and showed non-significant group effects 
(p>.10) for age and years of education.  
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2.3 MATERIAL AND ASSESSMENTS 
The cognitive and language tests used in the different studies are listed below according to an 
associated cognitive or linguistic domain. Free English translations and abbreviations of 
Swedish tests/tasks have been carried out when necessary. 
 
• Overall cognitive function. Mini-Mental Status Examination (MMSE) (Folstein et al.,  
1975) and The Montreal Cognitive Assessment Battery (MoCA) (Nasreddine et al., 
2005). 
• Language production. Boston Naming Test (BNT) (Kaplan, Goodglass & Weintraub, 
1983), Word fluency tests: Phonemic fluency: FAS (letters: f, a, s) and Semantic 
fluency: Noun and Verb (Tallberg et al., 2008), Repetition of long sentences (subtest of 
Assessment of Subtle Language Impairment; BeSS) (Laakso, Brunnegård, Hartelius & 
Ahlsén, 2000; Holmbro & Olsson, 2000) and Forward and Backward recall of automatic 
word sequences (Östberg, Farnaeus, Bogdanović &Wahlund, 2008). 
• Language comprehension. Inference and Logico-grammatical sentences (subtests of 
Assessment of Subtle Language Impairment; BeSS) (Laakso et al., 2000; Holmbro & 
Olsson, 2000), Information and Similarities (subtests of WAIS-R, Wechsler, 1981). 
• Reading capacity. Reading Speed (subtest of diagnostic read and write test; DLS) 
(Järpsten, 2002) and Read aloud words and non-words (subtest of read and write test; 
LS) (Johansson, 2002). 
• Memory. Digit Span; forward and backward (subtest of WAIS-R, Wechsler, 1981), 
Corsi Blocks, Rey Auditory Verbal Learning test (RAVL); total learning (RAVLT) and 
retention and Rey-Osterrieth test (R-O); retention (Lezak, Howieson & Loring, 2004; 
Schmidt, 1996) 
• Spatial ability. Block Design (subtest of WAIS-R, Wechsler, 1981) and Rey-Osterrieth 
test (R-O); copy (Lezak et al., 2004). 
• Executive function, attention and cognitive speed. Digit Symbol (subtest WAIS-R) 
(Wechsler, 1981), Trail Making Test; A and B (TMTa+b) and Stroop (Lezak, et al., 
2004; Golden & Freshwater, 2002). 
 
The overall intention with the test batteries was to cover a broad spectrum of cognitive and 
linguistic domains. The tests above were chosen as they are commonly included as valid and 
reliable tools as part of the clinical assessments of cognitive and language functions at the 
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Memory clinic / cognitive unit at Karolinska university hospital. The linguistic test battery has 
been validated among healthy elderly and patients at the Memory clinic, Karolinska University 
Hospital and is presented in a Swedish manual (SLUM; Tallberg, 2017). 
2.3.1 Study I 
2.3.1.1 The Swedish Linguistic Instrument of Medical Decision-making (LIMD) 
The vignette method was applied in the design of the Swedish Linguistic Instrument of Medical 
Decision-making (LIMD), which comprises three essential parts: (1) three vignettes (texts 
describing hypothetical clinical trials, both writing and orally), (2) Interview (orally) and (3) 
scoring protocol (based on linguistic features related to three LIMD-criteria: comprehension, 
evaluation and intelligibility). The participants received the vignettes, one at a time (same order 
for each participant) and kept the vignette ahead while answering the questions. The interviews 
(described below) were audio recorded and orthographically transcribed, which allowed 
different linguistic analyses (reported as a result in LIMD, study I and II as well as an analysis 
of certain responses reported in study III and IV). Test assessment, audio-recording and 
transcriptions were conducted by one test-leader (SS). The scoring of LIMD was conducted in 
two steps and by the same evaluator (IMT), who was blinded to the identity and diagnosis of 
each participant. IMT did not participate in the interviews. MDC according to LIMD was scored 
one vignette at a time and included both reading the transcription and listening to the audiotaped 
interview. No formal comparisons among the three vignettes were made during the scoring 
procedure, which followed the protocol accounted for below and included in total 79 
participants and standardised questions based upon the three vignette interviews (= 227 
interviews in total). A second scoring by IMT, to check reliability, using the same transcriptions 
and audio recordings, was performed after three months (blinded to identity and group). 
 
Vignettes 
The three vignette texts included in LIMD were produced from scratch by one of the paper’s 
co-authors (ES), an experienced researcher with knowledge in both biomedicine and medical 
ethics and were written in a style similar to texts used in patient information forms in Swedish 
ethical permits but condensed to not exceed two pages. The texts were then discussed and 
adjusted together with others clinicians and researchers in the field. The texts describe three 
different hypothetical clinical trial involving three different diseases: kidney disease, skin 
disease and hypertension. The three were chosen to include chronic diseases (as this is the case 
of AD) and diseases of different degrees of severity and risk. The language used in the vignette 
texts was chosen to reflect real informative texts used to recruit patients for clinical trials. The 
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three vignettes deliberately vary with regard to presumed risk and benefit. The two vignettes 
deliberately varied with regard to the presumed risks and benefits of participation. The content 
of the vignettes is summarised as follows: 
• The kidney disease vignette (241 words; high benefit and low risk) 
The fictive subject suffers from a serious progressive disease of the kidneys and is 
informed on the prognosis which implies extensive dialysis with a high probability of 
future kidney transplantation. The subject is invited to participate in a trial for a medical 
treatment which could stop the disease from further progress, with no expected serious 
side effects.  
• The skin disease vignette (587 words: low benefit and low risk) 
The fictive subject has a moderately severe inflammatory dermatological disease with 
stable symptoms. The subject is invited to participate in a trial for a new treatment that 
is rather inconvenient (drug infusion), with no hope for a permanent cure, and some risk 
of moderately severe skin effects (persistent skin lesions). However, another group of 
patients with very severe dermatological disease could be helped if the trial is 
successful.  
• The hypertension vignette (528 words, low benefit and high risk) 
The fictive subject has hypertension that is satisfactorily managed with standard 
antihypertensive medication. The subject is presented with a drug trial, and if she/he 
choose to participate, will change antihypertensive medication from the one presently 
used to a treatment that offers no better effect for the subject than the presently used 
drug, but could possible help other patients. The new drug has significant possible side 
effects, including the risk of one very severe (liver cancer) but with a low probability of 
occurring. (This vignette was designed to describe a trial that most likely would not be 
accepted by the ethical vetting board or the Swedish Medical Product Agency 
(“Läkemedelsverket”) due to this risk) 
 
Interview 
A standardized interview was performed on each participant and for each vignette. The 
interview considered the participants’ understanding, evaluation and choice regarding the three 
hypothetic clinical trials. The questions in the interview were asked by one individual (SS). The 
entire interview was audio reordered and orthographically transcribed. The LIMD interview 
included eight questions:  
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1. Describe in your own words what the text is about. 
2. Is the text about research or treatment?  
3. What disease is the text about? 
4. What is the doctor asking you about? 
5. Are there any risks associated with participation in the study? 
6. Are there any benefits of participating in the study? 
7. Why is the study important? 
8. Would you choose to participate? 
8.1.(If “yes”) Why would you choose to participate? / What would be the reasons 
for your participation? 
8.2.(If ”no”) Why would you choose not to participate?/ What would be the  reasons 
for not participating? 
 
Scoring protocol  
The LIMD scoring protocol was constructed in order to allow a wide distribution of scores, 
including three criteria: comprehension, evaluation and intelligibility and three vignettes with 
varied implied risks and benefits (kidney disease, skin disease and hypertension), resulting in a 
total LIMD score with a range from 0 to 27 points for each participant. To measure the total 
LIMD score of each individual, the test evaluators (IMT and SS) both read at least twice the 
entire transcribed interview and also listened to the interview by the audio recorded file. Also, 
it was important that all responses from the entire interview was used as a basis for the 
assessment since the score should be based upon the sum of the overall responses (i.e. not based 
upon one single response to one particular question).  Using a linguistic analysis, based on both 
transcribed and oral data, as well as taking the listener’s perspective, the intention was to 
analyse the verbal utterances rather than trying to interpret the thought of the respondents. 
Therefore, the procedure was based on a systematic predefined protocol to analyse different 
linguistic signs in their utterances (e.g. syntax, vocabulary), prosody (e.g. strength of voice) and 
pragmatics (e.g. meta-linguistic devices like irony, consistency in the speech). Particular 
attention was paid to linguistic markers for estimation in subjects’ reasoning such as ‘bad, good, 
very and small’, which could be signalling if risks and benefits had been adequately addressed. 
When measuring MDC by LIMD, it was considered important to capture the subjects’ actual 
comprehension of the given context, i.e. the capacity to verbally describe and reason about the 
information in her/his own words, rather than the mere ability to automatically repeat the words 
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from the vignette. In other words, the score was affected by whether the subject was reading on 
the inside or whether she/he used own words. 
 
The scoring for each vignette; (1) kidney disease trial, (2) skin disease trial and (3) hypertension 
trial, was calculated in the same order for all subjects. The principles for scoring in each 
respective vignette were based on three criteria; comprehension, evaluation and intelligibility 
of choice. Each criterion received a separate score in the range between 0-3 points/criteria based 
on what the participant actually communicated during the entire interview, each vignette 
evaluated separately. The sum of the score, including all three criteria in all three vignettes (3 
criteria x 3 vignettes x 0-3 points = range 0-27 score) equaled the total LIMD score per 
participant. The LIMD scoring protocol defined the requested features for each respective 
scoring point, 0,1,2 and 3, for each respective criterion. An illustrative extract from the LIMD 
scoring protocol, concerning score 0 (minimum) and score 3(maximum), is presented below 
(categorized within each criteria). 
 
• Comprehension - ability to perceive, understand and account for the content. 
Scoring was based on the assessor’s estimation of how closely the subject’s responses 
corresponded to the content of the vignette. Linguistic features such as independence of 
utterances (i.e. not word-for-word replays), accuracy, inferences, relevance (if 
utterances were adding new information or not), coherence and specificity. 
0 points – The content of the vignette was not communicated i.e. the evaulater was most 
certain that the vignette's information had not been perceived by the participant (e.g. 
does not answer fully on several questions about the content such as answers 
incompletely to the majority of questions about the content of the vignette and / or the 
answers contain "error response" and/or "misunderstanding" and/or answering "I do not 
Know" and/or "I do not Remember" and/or the participant is reading aloud, i.e. no own 
language use). 
3 points – The content of the key information of the vignette was communciated well-
defined and distinct i.e. the evaulater was most certain that the vignette's information 
had been well perceived by the participant (e.g. does answer fully on several questions 
about the content. No "error response", "misunderstanding" nor any phrases like "I do 
not know", "I do not remember". The participant uses own words when retelling about 
the content).  
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• Evaluation - ability to perceive and value risks and benefits. 
Scoring was based on the extent to which it was shown in the utterances that the 
participant had evaluated the risks and benefits of the fictive clinical trials, and how 
these identified risks and benefits were described. The scoring was also considering 
coherence between utterances, how key words occurred, use of evaluating language, 
specificity and prosodic elements. 
0 points – The implied risk and benefit described in the vignette was not communicated 
i.e. the evaulater was most certain that the risk and benefit described in the vignette 
information had not been perceived by the participant (e.g. neglects to explain either the 
risks or the benefits, occourence of "error response", signs of "misunderstanding" or 
respnses like "I do not remember", unreasonable or lack of reasoning or non-balance of 
risk and benefit to each other. Does not take into account the complete context). 
3 points - The implied risk and benefit described in the vignette was communicated in 
a well-defined and distinct manner i.e. the evaulater was most certain that the risk and 
benefit described in the vignette information had been well perceived by the participant 
(e.g. explains and evaluate well the given risk and benefit. Balance risk and benefit to 
each other. Taking into account the full context). 
 
• Intelligibility of choice  -ability to express and formulate a decision and its motivation. 
Scoring was based on the assessor’s estimation of how far the participants was able to 
communicate choie and its motivation in an itelligible and relevant way (in relation to 
the participant’s previous utterances as well as to the content of the given information). 
Language features considered to be relevant to interpret the decision were for example 
prosodic elements, vocabulary, specificity, occurrence of contradictive utterances 
and/or words for vagueness. 
0 points – Lack of ability to communciate a choice based on the vignette information 
and previously reasoning i.e. the evaulater was most certain that the participant’s 
communicated decision (if it was at all communicated) not could be considered as a well 
informed consent. (e.g. absence or partial lack of hypothetical reasoning: giving 
responses contradictory to own evaluation, motivation and/or based upon a clear 
misunderstanding of the content of the vignette and/or not answering the question, 
giving an answer not appropriate to the context or to her/his previous utterances). 
3 points - Ability to communciate an informed consent in a well-defined and distinct 
manner  i.e. the evaluater was most certain that the participant’s communicated decision 
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could be considered as a well informed consent. (e.g. good ability in hypothetical 
reasoning, transfers the vignette's information to herself/him and answers clearly based 
on the current hypothetical context. Answers clearly and with a well-founded "yes" or 
"no", the decision is clearly stated and coherent to the participants’ own motivation and 
also to the content of the vignette).  
2.3.1.2 Screening of cognitive function  
Mini-Mental Status Examination (MMSE; Folstein et al., 1975). 
2.3.2 Study II 
2.3.2.1 The Swedish Linguistic Instrument of Medical Decision-making (LIMD) 
See above (study I). 
2.3.2.2 Test battery 
Cognitive and linguistic functions were assessed, using in a total of 27 test measurements. See 
section above: material and assessments (2.3), excluding MoCa. 
2.3.3 Study III 
2.3.3.1 Screening of cognitive function  
Mini-Mental Status Examination (MMSE; Folstein et al., 1975). 
2.3.3.2 The Swedish Linguistic Instrument of Medical Decision-making (LIMD) 
See above (from data collection I, see study I: 2.3.1.). 
2.3.3.3 Vignettes 
Two vignettes (from data collection I, see study I: 2.3.1. were chosen to illustrate greatest 
contrast in probable risk and benefit (kidney disease; low risk and hypertension high risk). 
2.3.3.4 Questionnaire 
Four standardized questions were used Q1-2 (from data collection I, see study I: 2.3.1., 
numbered as 8 and 8.1) and Q3-4 (were not included in the LIMD, but performed within the 
same data collection I). The questions were given orally and the total interview was audio-
recorded followed by an orthographical transcription which enabled analysis of the responses. 
Q1 and Q3 were asked to all participants. Q2 and Q4 were open follow-up questions, asked to 
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1. Would you be willing to participate?  
2. Why would you be willing to participate?   
3. If you were unable to make your own decision, would it be acceptable for someone 
else to make the decision regarding your participation?  
4. Who would you prefer to make the decision in your place? 
 
After transcription and analysis, the different reasons for participation were divided into five 
informal subcategorizes by the test leader (SS) to facilitate a comparison between groups and/or 
trials. Co-author (IMT) gave a second opinion on the analysis and sub-categorisations of 
answers. If the willingness to participate (answer to Q1) was verbalised unclearly, the choice to 
participate or not was controlled by the follow-up question Q2: “Why would you be willing to 
participate?” (giving the participant the chance to deny an interpreted willingness). No response 
options were given. 
2.3.3.5 VAS 
Visual analogue scales (VAS, 0-100 mm) were handed out to the participant (one at a time) by 
the test leader (SS) after the interview of each vignette. The VAS served to estimate the 
participant’s evaluation of perceived personal risk (“risk”), personal benefit (“own-benefit”) 
and benefit for others (“other-benefit”) involved in the two trials. SS performed the test 
procedure and analysis (blinded to group). 
2.3.4 Study IV 
Study IV (work in progress) is a qualitative study, applying semantic analysis of selected 
utterances (which were considered to be illustrative examples of meaning and lack of meaning) 
based on previously collected material (data collection I) in the form of recorded interviews and 
transcripts: (1) one vignette, (2) a standardised interview (Q1-8 from the LIMD) 
2.3.4.1 The vignette 
The kidney disease vignette describes a hypothetical clinical trial that offers a potentially high 
degree of benefit at a low degree of risk (see study one; 2.3.1.1. vignettes). 
2.3.4.2 Standardized interview 
The interview included the eight questions from the LIMD-interview, covering three criteria of 
MDC (questions 1-8 from the LIMD, see study I; 2.3.1.1). The interview was given orally 
(based upon information given both in written form and orally) and lasted approximately four 
minutes per participant. The interview was audio recorded and orthographically transcribed (as 
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part of data collection I). Note, the interviewer closely followed the script of the standardised 
questionnaire, i.e. no spontaneous interaction between interviewer and participant was 
permitted. The participants were allowed to reread the text (vignette) while answering the 
questions. Answering the questions called for sufficient comprehension and the ability to 
distinguish between the hypothetical (vignette) and other situations in addition to being able to 
respond orally to the questions in a rational manner.  
2.3.4.3 Semantic analysis of selected utterances 
The inclusion of the four participants, in study IV was based on a qualitative selection among 
transcribed data from data collection I (the LIMD-interview) to represent speech acts from both 
conditions of impaired cognition due to AD and presumed normal cognitive functioning in the 
group of HC, respectively. Selected utterances from each participant were examined word-by-
word and line-by-line. The selection of utterances was based on the aim of capturing illustrative 
examples of sense-making and figurative speech based on the reasoning for possible 
participation in the fictive clinical trial. 
 
The analysis considered sense-making and the way linguistic signs (e.g. words, literal concepts) 
of time, place and person occurred. This linguistic approach was influenced by previous studies 
of irrelevant speech in dementia (Tallberg, 1999; Tallberg, 2000), but from a somewhat new 
perspective as the utterances were the product of an experimental context in which the 
participant was instructed to take the perspective of a hypothetical self (an individual with a 
kidney disease described in the vignette text) in a hypothetical situation (the fictive clinical trial 
described in the vignette text) at an unspecified time. It was presupposed that these participants 
would, to various degree, move cognitively between predefined cognitive situations, as 
described by Tallberg (2001) as: “the contexts a speaker constantly moves between, including 
the present context and memories of the past and the future”. Based upon this presumption, five 
cognitive situations associated to the context of the current experimental study, were defined:  
 
• The vignette situation. A hypothetical situation, clearly stated as fictive in terms of 
person, time and place. The characters were a doctor working with clinical trials and a 
patient with a kidney disease, invited to participate in a clinical trial. The text is worded 
in the present tense and is intended for and addressed to the reader of the text (with the 
pronoun you referring to the hypothetical patient, i.e. the participant in current study). 
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• Other imagined situation. Any invented situation, imagined by the participant, 
probably totally or partly unknown to the listener, assumed to be constructed from the 
participant’s previously experiences or somewhat related to other predefined situations 
(the vignette, the participant’s own life, experimental and the situation at hand). 
• The own life situation. The participant’s actual real-life situation (current and past), 
which may or may not bear similarities to the vignette situation.  
• The experimental situation. This situation began before the interview took place, when 
the participant agreed to the terms of the current experimental study, which included 
two speakers: the participant (the subject for the interview, either AD or HC) and the 
interviewer (test leader; TL) who reads the vignette aloud. The TL began the interview 
with the words "Imagine that you…"  followed by the standardised questions. 
• The speech situation. A shared present situation, referring to the ongoing interview 
situation, agreed upon by both speakers (me and you) occuring in present time. 
Linguistic signs in the verbal utterances such as choice of pronoun and tense can be valuable 
clues for the listener who is trying to interpret the meaning of the utterances and what the speech 
act is referred to as followed (a) from what mental situation (e.g. here/there and this/that), (b) 
from what person (noun – e.g. she/he, I, you and them) and (c) from what time (tense-e.g. 
current, past or future). To distinguish different situations (hypothetical and other), the speech 
is preferably also underscored by additionally linguistic explicit signs such as the conjunctive 
conditional, if or verbally terms emphasising the mental situation from which the speech is 
derived, such as hypothetically or supposing that. 
2.3.5 Study V 
Different assessment tools were included in current version of study V (work in progress): (a) 
a test battery including cognitive and linguistic tasks and (b) KIMB, including the target word 
task (KIMB-t; measured by score and time in seconds) and a questionnaire (KIMB-q; measured 
by score and time in second). The tasks are presented in short below (but only the results of 
KIMB-t score will be reported and discussed in the current thesis).  
2.3.5.1 Cognitive test battery 
Six cognitive tests / tasks were included. Four of the tests had strong association to MDC 
(measured by LIMD in study II): 
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• Rey Auditory Verbal Learning Test (RAVLT, Lezak et al., 2004; Schmidt, 1996). 
• Repetition of Long Sentences (BeSS; Laakso et al., 2000; Holmbro & Olsson, 2000). 
• Inference (BeSS; Laakso et al.,  2000; Holmbro & Olsson, 2000). 
• Reading Speed (Järpsten, 2002). 
 
Screening test of overall cognitive function: 
• Montreal Cognitive Assessment Battery (MoCA, (Nasreddine et al., 2005).  
 
One cognitive task we hypothesized would not correlate to KIMB:  
• Word sequence production (Östberg et al., 2008). 
2.3.5.2 Kliniskt Instrument av Medicinsk Beslutsförmåga (KIMB, English ”clinical 
instrument of medical deicision-making capacity) 
 
KIMB, target word (KIMB-t). The design of the KIMB target word task (abbreviated in the 
current thesis as KIMB-t) is similar to the Reading Speed task (DLS; Järpsten, 2002) as it 
consists of a text (written by SS and LT) including several sets of embedded brackets […] each 
containing three possible words, where the one correct target word should be underlined as fast 
as possible. However, the text of KIMB-t differed from the Reading Speed task in that it 
describes a fictive clinical trial and has lower number (13 versus 36) of embedded brackets (i.e. 
the participant is expected to read through the entire text). The text describes a fictive individual 
who is suffering from a fictive disease and is offered participation in a clinical trial with 
presumed high risk and low personal benefit. The text includes information regarding i.e. the 
procedure as well as the possible risks and benefits of a participation. The text in KIMB has 
approximately the same number of words (n= 327) as the vignette texts used in LIMD. The 
KIMB-text, was during its construction, analysed with the SVIT language model (by KHM, 
Heimann Mühlenbock, 2013) to study its readability and to ensure that it was constructed with 
similar language characteristics as the text of the Reading Speed task (DLS; Järpsten, 2002), 
which previously has shown high predictive value for assessing MDC by LIMD (Stormoen, et 
al., 2014). The SVIT model includes analysis of a combination of linguistic properties such as 
for example vocabulary (i.e. incidence of difficult word) as sentence structure (i.e. mean length 
of utterance) (Heimann Mühlenbock, 2013). 
 
The scoring procedure for KIMB-t was to count the correct responses (max 13) and measure 
total time (in seconds) taken to complete the task. Each correctly identified word earned one 
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point, whereas wrong choice of the word, no word or several words chosen within the same 
brackets earned no points. Several different cognitive and linguistic skills were required to 
identify the correct target word in each bracket, such as reading capacity, word and language 
comprehension, inference and working memory. The instruction was to read the text and 
underline one target word in each bracket as fast as possible. An excerpt from KIMB-t is given 
below: 
“…We are investigating and testing the effect of a new drug, Auxilium, which is expected to 
alleviate the symptoms of the Dolor disease. To participate in this [surgery study contest] the 
participant will be assigned to one of two trial groups, where one group will try Auxilium and 
the other will receive a substance with no therapeutic effect, so-called [water caffeine 
placebo]…” 
 
KIMB, questionnaire (KIMB-q).  
The KIMB questionnaire was composed of six written questions with multiple-choice answers: 
1) What is the text about, 2) What are the risks associated with participating in the study? 3) 
What are the benefits if participating in the study? 4) Estimate the risks of Kim’s participation, 
5) Estimate the benefits of Kim’s participation, 6) Would you advise Kim to participate in the 
study? The participants were allowed to re-read the text while answering the questions to lessen 
the burden on memory capacity. The instruction was to complete the task as quickly as possible. 
Each correct chosen answer earned one point, while a wrong answer, no answer or multiple 
answers earned no points. The scoring procedure of KIMB-q was to count the correct responses 
(range 0-6 scores) and measure the total time taken (in seconds) to complete the task. 
2.4 STATISTICAL ANALYSIS 
Statistical analysis was conducted using SPSS™ version 22 (studies I-III) and version 23 (study 
V). The rejection level was set to p<0.05. Descriptive statistics (mean ± standard deviation) 
were used to present characteristics and test results for the three groups of participants (studies 
I-III and V). 
 
Principle Component Analysis (PCA)  
PCA was conducted in studies I and II and presented and discussed in terms of 
component/factor scores and/or loadings as follows: 
• Study I. The correlation matrix, using eigen-values >1 as criteria for number of 
components and varimax rotation in order to find a simple structure of all 27 items 
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(measurment scores) in LIMD. To find out if LIMD-total score represents a uni-
dimensionsal variable, independent of criteria and vignettes. 
• Study II. PCA was performed to find a simple structure of the cognitive tests battery 
(lessen the number of measurments into independent components including as much as 
possible of the total variance). Eigen values >1 were used to select number of 
components (all components should have high loadings; meaning >.70, in at least two 
test measures). Varimax rotation was applied to identify a parsimonious structure. 
 
Stepwise linear regression 
• Study II. Stepwise linear regression was used to examine the association (common 
variance, r2) between the total LIMD score and the four identified PCA components. 
The degree of importance for each component toward LIMD was presented as β 
weights. The first regression analysis was performed with total LIMD score as 
dependent variable and the four PCA components: (1) verbal knowledge, (2) episodic 
memory, (3) cognitive speed and (3) working memory. Further regression analyses 
added demographic characteristic (age, gender and education) and dementia severity 
(MMSE) to the four components. 
 
The Pearson correlation coefficient  
The Pearson correlation coefficient (PCC) also referred to as Pearson's r, was conducted in 
studies I, II and V as follows:  
• Study I. (1) interrelationship between LIMD and demographic characteristics as well as 
cognitive severity by MMSE within groups (AD, MCI and HC), (2) reliability:  (2a) 
correlation between evaluations by two different examiners and (2b) correlation 
between two evaluations by the same examiner and (3) validity: interconcistency 
between the three LIMD criteria (comprehension, evaluation and communication of a 
choice) and the three vignettes (nine variables). 
• Study II. Correlations among pairwise variables (test-test and test-component) of LIMD. 
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Analysis of variance (ANOVA) 
One-way ANOVA (to compare means of two or more diagnostic groups), followed by Tukey’s 
post-hoc t-test (conducted to confirm where the differences of test results occurred between 
groups) was applied in study I, II, III and V as followed: 
• Study I. (1) Examination of groups (AD, MCI and C) was comparable in demographic 
characteristics as demonstrated by non-significant group effects (all p>.1) according to 
one-way (group) ANOVAs, (2) Investigation the differential diagnostic power by means 
of ANOVA using total LIMD score as dependent variable and diagnostic group as 
independent variable and (3) investigation of differential pattern due to vignettes by a 
repeated measure (three vignette scores) two-way ANOVA with the three diagnostic 
groups as independent variables and mean LIMD score for each vignette as dependent 
variable. 
• Study II. Analysis of group differences in age, education, LIMD, MMSE and all 
cognitive test measures. Tukey’s post hoc t-test was used to analyse possible pairwise 
group differences. The effect size was reported as degree of explained variance in 
ANOVA’s (eta, η2).  
• Study III. (1) Investigation of whether the factor group (AD, MCI and HC) and 
willingness to participate (acceptance to participate or not) had an influence on cognitive 
severity (MMSE) and MDC (by LIMD) in the two clinical trials (with varied applied 
risk and benefit) and (2) analysis of the pattern of results regarding trial, estimate and 
group in each trial and type of estimation. 
• Study V. Analysis of possible differences between the groups AD, MCI and HC 
regarding age, educational level and score on KIMB. 
 
Multivariate analysis of variance (MANOVA) 
• Study III. (1) Two-way (type of trial and type of estimation as within-subject factors) 
MANOVAs were used to determine whether there were any differences between 
diagnostic groups (independent variable, between-subjects factor) on two continuous 
dependent variables: trial and estimation), followed by Tukey’s post-hoc t-test (to 
confirm where the differences occurred between groups), (2) VAS estimation of risk 
and benefits (risk, own-benefit and other-benefit) in the two hypotetical trials as within-
participants’ dependent variables and groups as independent variable was analysed and 
(3) acceptance to participate (answering ”yes” to Q1) in the two trials and acceptance 
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of a proxy as decision maker (“yes” to Q3) in the two trials as within-participants’ 
dependent variables and groups as independent variable. 
2.5 ETHICAL CONSIDERATIONS 
The studies included in the thesis were approved by The Regional Ethics board at Karolinska 
Institutet, Stockholm: Dnr. 2008/1276-31/2, 2009/1764-32 and 2015/1516-32. All participating 
individuals, regardless of group, were given oral and written information about the study and 
gave their own informed consent to participate. 
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3 RESULTS 
3.1 STUDY I 
3.1.1 Scoring  
All results are presented on group level (AD, MCI and HC) and the LIMD score refers (if 
nothing else is specified) to the mean and total LIMD score (mean value between two ratings 
by the same examiner (IMT) of total LIMD score, including all three vignettes and all three 
MDC criteria; minimum score 0 and maximum score 27). The mean and standard deviation on 
LIMD score in the different groups were; AD= 8.0±7.1 (range 0.5-22), MCI= 17.1±6.1 (range 
2-27) and HC= 22.4±4.8 (range 9-27). 
3.1.2 Reliability 
Test reliability was calculated as inter-rater reliability (the degree of agreement of total LIMD 
score among two different examiners, IMT and SS) and intra-rater reliability (the degree of 
agreement of total LIMD score among repeated ratings by a single examiner IMT). Both inter- 
and intra-reliability were found to be good (r =.89, p<.01 vs 0.94, p<.001). Furthermore, the 
correlation between first and second evaluation within groups were all at high levels (AD, r = 
.92; MCI, r = .90; HC, r =.88, all p <.001).  
3.1.3 Validity 
3.1.3.1 Internal consistency  
The associations between the three LIMD-criteria and the three vignettes of LIMD (in sum nine 
variables), were all high, between 0.64 and 0.94, and strongly significant (all p<.001). One 
single component accounted for approximately 80 % of the total variance. All variables were 
strongly loaded in this component (in range between r=.86 and r=.93). 
3.1.3.2 Differential diagnostic power 
Group differences on total LIMD score were strongly significant (F=40.60, df=2/76, p<.001, 
eta2=.52) and groups differed significantly (t=4.51, df=40, p<.001; t=3.71, df=57, p<.001; AD 
vs. MCI and MCI vs. HC). The interrelationship between LIMD score and demographic 
characteristics (age, gender and education) and MMSE score within groups was not significant 
between LIMD score, age or gender in any group, but a positive correlation was found between 
level of education and total LIMD score in HC (r= .54, p<.001) and a significant association 
between total LIMD score and MMSE in all groups. 
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No significant differences pattern (F=1.03, df=1/76, p>.1) was found among total LIMD score, 
the three vignettes (Kidney disease, Skin disease and Hypertension) and the three groups (AD, 
MCI and HC). Furthermore, the interaction between vignettes and diagnostic groups was not 
significant (F=1.98, df=2/76, p>.1), although the groups were clearly separated across vignettes 
(F=39.46, df=2/76, p<.001). 
 
The three groups differed significantly in total LIMD score including after exclusion of possible 
confounding demographic factors (age, gender and education) and cognitive severity (by 
MMSE; F=7.76, df=2/70, p<.001). Three of the four covariates were significantly associated 
with total LIMD score: age (F=8.32, df=1/70, p<.01), education (F=7.43, df=1/70, p=<.01), and 
cognitive severity (MMSE; F=17.82, df=1/70, p<.001), though gender was not a dependable 
covariate. The analysis was repeated also considering the three criteria measured by LIMD 
(comprehension, evaluation and intelligibility of choice) and possible confounding factors (age, 
gender, education and MMSE) and no significant effect was found. However, the effect of 
diagnostic group remained significant (F=4.92, df=2/70, p<.01.). 
3.2 STUDY II 
3.2.1 Scoring 
Descriptive statistics of LIMD and the 27 cognitive and linguistic measurements were reported 
as followed: AD performed worse than MCI and HC (and MCI performed worse than HC). 
Significant group differences were shown total LIMD score and the measurement of cognitive 
and linguistic functions (p<.05).  
 
AD and HC differed significantly in all tests (p<.05). AD and MCI differed significantly on 
LIMD and several cognitive test measures (e.g. language production and comprehension, 
reading capacity and episodic memory; p<.05). MCI and HC differed significantly on LIMD 
and several cognitive tests (e.g. language production, reading capacity, spatial ability, short-
term memory, episodic memory, executive function, attention and speed; p<.05). 
3.2.2 LIMD versus cognitive and linguistic tests 
The 27 cognitive measurements were found to aggregate into four components corresponding 
primarily to overall verbal knowledge, episodic memory, cognitive speed and working memory 
and accounted for approximately 70% of the variance in LIMD. Total LIMD score correlated 
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significantly to the four components (possible predictors) (multiple r=.86, adjusted r2=.73, 
F=40.23, df=4/55, p<.001) as followed: the “verbal knowledge” component (beta=.66; p<.001), 
the “episodic memory” component (beta=.43; p<.001), the “cognitive speed” component 
(beta=.32; p<.001) and the “working memory” component (beta=.23; p<.01).  
 
The single tests measure with highest correlation to LIMD total score was the language task: 
“Reading Speed” (included in “the verbal component”), which evaluates e.g. reading capacity, 
comprehension, speed and inference based on a written context (r=.77, beta=.38; p<.001). The 
second strongest correlation between LIMD and single tests was “RAVLT” (=total score; 
included in “the episodic memory component”; r=.71; beta=.26, p<.001), which evaluates e.g. 
short-term auditory-verbal memory. Inclusion of additional measurements showed significant 
contribution by the single tasks: “Inference” (included in “the verbal knowledge component”, 
r=.75; beta=.23; p<.001), which evaluates e.g. ability to comprehend and draw a conclusion 
based on an orally and written context and “Sentence Repetition” (included in “the verbal 
knowledge component”; r=.67; beta=.22; p<.001), which evaluates e.g. verbal repetition of long 
sentences, attention and working memory. 
3.3 STUDY III 
3.3.1 Acceptance to participate 
The study reported significant difference between the two hypothetical trials in terms of overall 
willingness to participate in the hypothetical trials (who accepted answered “yes” to question 
1, regardless of diagnostic group; F=44.1, df=1/71, p<.001, ε2=.38) as followed:  
 
Higher willingness to participate in the low-risk trial, Kidney disease trial (approximately 90%) 
compared to the high-risk trial, Hypertension trial (approximately 40%). No significant 
difference was found among groups regarding willingness to participate in each trial (p>.1) and 
no significant interaction among groups and trials was shown (p>.1). Significant difference in 
MDC (measured by LIMD) was found between those participants who accepted to participate 
(who answered “yes” to Q1, regardless of diagnostic group) in the low-risk trial (F=6.60, 
df=1/73, p<.01, ε2=.09) in comparison to those who accepted to participate in the high-risk trial 
(F=3.86, df=1/73, p<.01, ε2=.05).  
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• Individuals who accepted to participate in the low-risk trial (n=66) showed stronger 
MDC (by LIMD; 18±8) than individuals who did not accept to participate (n=8; LIMD; 
10±9).  
• Individuals who accepted to participate in the high-risk trial (n=31) showed lower MDC 
(by LIMD; 14±8) in comparison to individuals who did not accept to participate (n=43, 
LIMD; 18±8). Notable, no significant difference in cognitive severity (by MMSE) was 
shown between individuals who accepted or not to participate in each trial (p>0.1).  
3.3.2 Reasons for participation 
The reasons for participating in each trial were analyzed for all participants who communicated 
willingness to participate (the low-risk trial, n=66/74 and the high-risk trial, n=31/74). 
Hypothetical participation was motivated by the response to question 2: “Why would you be 
willing to participate?”. After transcription the different reasons for participating were divided 
into five subcategories, listed below, with some examples of responses within each category):  
 
• Own-benefit: (the low-risk trial, n=26/66; the high-risk trial, n=5/31) 
“…because I want to feel good…” / “…I like to take advantage from medical controls 
within the research project, which may be beneficial for myself (the low-risk trial, 
• Help other: (the low-risk trial, n= 12/66; the high-risk trial, n= 14/31) 
“…contribute to a better treatment for others in the future”/ “…by participation in a 
research project one can possible make a difference for others…”  
• Own benefit and Help other: (the low-risk trial, n= 16/66; the high-risk trial, n=0/31) 
“…well for my own benefit as I hopefully can get avoid a Kidney transplantation and 
so that I maybe can contribute to help other in the future…” / “…one reason to 
participate is that me, myself can benefit from it and in addition one can also contribute 
to help others…”  
• Support research and Make good: (the low-risk trial, n=4/66; the high-risk trial, 
n=10/31) 
“…the reason is to move forward with research and all those things…” / “…I believe 
one has a duty… by participating and in that way contribute to research…”  
• Other reason: (the low-risk trial, n=6/66; the high-risk trial, n=2/31) 
“… yes well I guess I do not have not much to lose…” / “…it is difficult to explain 
why…”  
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The overall primarily reason to participate in the low-risk trial was reported as “own-benefit” 
(approximately frequency across groups 40%), while “help others” was the most commonly 
identified reason for participation in the high-risk trial (approximately frequency across groups 
50%). 
3.3.3 Estimations of risk and benefit  
A significant difference was found between the two trials across groups (p<.001) as well as of 
types of estimations (by VAS; 0-100 mm) across groups (p<.001). No significant group 
differences were found between MCI and HC concerning estimations of benefits or risk in either 
trial (all p>0.1).  
 
• In the low-risk trial, significant group differences concering mean VAS score were 
shown regarding “other-benefit” (F=5.38, df=2/71, p<.01) as followed: AD estimated 
“other-benefit” lower than MCI and HC (p<.05; AD (70), MCI (84) and HC (85)).  
• In the high-risk trial significant group differences on mean VAS score were shown for 
“own-benefit” (F=5.05, df=2/71, p<.01) and “risk” (F=8.96, df=2/71, p<.001) as 
followed: AD estimated “own-benefit” higher than MCI and HC (p<.05; AD (50), MCI 
(26) and HC (26)) and estimated “risk” lower than MCI and HC (p<.05; AD (33), MCI 
(62) and HC (66)).  
3.3.4 Attitude toward proxy 
Significant difference was observed between the two trials regarding overall willingness to 
accept to a future proxy between the two trials (p<.001): Higher acceptance of proxy in the low-
risk trial (approximately 70%) compared to the high-risk trial (approximately 40%). AD 
patients were more willing to accept proxy in the high-risk trial compared to HC (p<.001; AD 
(60%) vs. HC (22%)). No group difference was shown regarding acceptance of proxy in the 
low-risk/high-benefit trial (p>.1). Also, AD patients showed an overall positive attitude to 
proxy and no difference in acceptance to proxy between the two trials (p>.1), while acceptance 
to proxy differed between trials in the groups of MCI (p<.01) and HC (p<.001). As shown in 
the transcriptions and analyses of the responses to: “Who would you prefer to make the decision 
in your place?” several different choices of future proxy were communicated among all 
participants (who accepted a proxy in either trial; the low-risk trial, n=52/74 and high-risk trial, 
n= 28/74). Their responses were divided into three informal subcategories listed below with 
some examples:  
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• Family member: (low-risk trial, n=45/52; high-risk trial, n=26/28) 
”…my wife or son...” / “…my daughter or son in law…” / “...my husband or 
daughter..” 
• Physician: (low-risk trial, n=3/52; high-risk trial, n=1/28)  
“…some doctor…”. 
• Family member and Physician: (low-risk trial, n=4/52; high-risk trial, n=1/28). 
“…my partner or son together with a physician…” / “…close family in consultant with 
a physician…”  
 
The study was reported that “a family member” was the most common identified response 
(considered each and the sum of the two trials) when the participants were asked who they 
preferred hypothetically would make the decision in their place (approximately 90%).  
3.4 STUDY IV 
The AD patients demonstrated fluent but perseverative and unspecific speech displaying some 
semantic abnormalities. It was unclear to some extent which cognitive situations (as described 
by Tallberg, 2001) they were moving between (suggesting difficulties to mentally transform 
themselves within and between given situations; the vignette, other imagined, own life, 
experimental, and the on-going speech situation). A tendency or preference to remain in the 
present own-life situation, not taking the perspective of the fictive subject in the hypothetical 
text, was noted. Hence, the individuals with AD seemed to struggle to separate the hypothetical 
situation from their own present reality such as motivating a choice to participate in the 
hypothetical trial due to the real-life situation (e.g. “many children and grandchildren”). Use of 
linguistic signs for time and place, conditional tenses and conjunctions was very sparse. Also, 
general use of pronouns did not clearly show a distancing between their own real selves and 
their hypothetical selves for the purpose of the information given in the vignette. The analysis 
could also show that the responses by the HC were fluent and more informative, detailed and 
moved logically and concisely between the different cognitive situations. This movement was 
conveyed by the use of linguistic signs for time and conditionals expressed through both tense 
and the conjunction word If, which reveals a distance between the individuals real and 
hypothetical self.  
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3.5 STUDY V 
3.5.1 KIMB-t 
3.5.1.1 Comparison of groups 
One-way ANOVA showed a significant group difference on KIMB-t (p <.05). Tukey’s post-
hoc test revealed that KIMB-t score was significantly higher for HC than AD group (p <.05) 
while no significant difference was found between HC and MCI nor between AD and MCI. 
There was also a significant difference between the groups regarding time to complete the task 
(p <.01). Tukey’s post-hoc test showed that the time to complete the task was significantly 
longer for AD than HC (p <.01) and MCI (p <.05), while no significant difference was found 
between HC and MCI.  
3.5.1.2 Sensitivity and specificity  
The significant differences on group level by the combined group (AD + MCI) were a 
prerequisite for the calculations on sensitivity, specificity and predictive values. If KIMB-t cut-
off value was set to 12 points (allowing one error), the sensitivity was low (37 %) but specificity 
was high (94 %). 
3.5.1.3 In comparison to cognitive and linguistic tasks 
The Pearson product-moment correlation coefficient was calculated to investigate associations 
between scores of KIMB-t task and results of the six comparable tests (including all 
individuals), (effect sizes, calculated as r2). KIMB-t score correlated significantly and 
positively to to cognitive severity by MoCA (p <.01; r= .46; r2=.21) and to the four cognitive 
and linguistic tasks previously associated to MDC (by LIMD, see study II): Repetition (p <.01; 
r= .48; r2=.23), Inference (p <.01; r= .45; r2= .20), Reading Speed (p < .01; r= .45; r2= .21) and 
RAVLT (p < .05; r=.30; r2= .09). 
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3.6 IN SUM 
I. LIMD, the Swedish linguistic instrument of medical decision-making has demonstrated 
good psychometric features, which high-lights the impact of including communicative 
and linguistic features when assessing the decision-making capacity for research in 
patients with cognitive impairment. 
II. Multiple factors are involved in MDC as measured by LIMD, but the components of 
overall verbal knowledge, episodic memory, cognitive speed and working memory were 
strongly correlated to the capacity and the Reading Speed task, which assesses both 
rapid reading and understanding of a text, showed the strongest correlation to total 
LIMD score. 
III. Medical decisions by the patients should be interpreted with caution already in early 
stages of AD as their acceptance to participate in high risk trials may be due an 
insufficient decisional ability to estimate risk. 
IV. Irregularly used linguistic signs for referring to time, place and person may lead to 
difficulties in interpreting and understanding the sense-making in speech.  
V. Preliminary results indicate that KIMB-t could serve as a brief Swedish reading tool to 
detect patients with reduced capacity to give informed consent (based on written 
information). 
  
  41 
4 DISCUSSION 
4.1 METHODOLOGICAL TOPICS  
4.1.1 Procedure 
The PhD-project is based upon empirically research and includes five studies, which all, by 
different approaches take a linguistic approach to the topic of medical decision-making among 
patients with impaired cognitive function: (1) developing two new linguistic tools (LIMD and 
KIMB) for evaluating different aspects of MDC (studies I and V); (2) investigating cognitive 
and linguistic correlates of MDC as measured with LIMD (study II and V) and (3) analysing of 
verbal utterances in terms of choices and decisional reasoning (studies III and IV). The scientific 
complexity of medical decision-making in dementia can be discussed from two central themes:  
 
1) Inconsistency - Estimation of decision-making is per fact limited to the individual's 
ability to make a decision and reason at one specific occasion (the exact time and context 
in which the capacity is being assessed). The capacity may fluctuate depending on what 
cognitive situation the participant is referring to in relation to the hypothetical situation 
from which the questions are based upon. If the capacity was considered another day or 
in another context, the result might have been different. Also, the capacity is expected 
to constantly change due to the progressive cognitive decline following the 
neurodegenerative disease. Hence, the capacity is not static but changeable, due both to 
individual causes (e.g. patients’ status) and contextual causes (e.g. complexity of 
decisional situation and time given). Sufficient or insufficient capacity must always be 
assessed on an individual basis and sometimes needs to be reconsidered.  
2) Interdisciplinary - The field is multidisciplinary and determination of capacity must be 
viewed upon in the light of a broad and deep discussion including several research areas 
such as linguistics (e.g. semantics and pragmatics), speech and language pathology (e.g. 
language disorder), medicine (e.g. differential diagnosis and neuropathological 
processes), neuropsychology (e.g. cognitive predictors), medical ethics (e.g. issues 
related to autonomy and protection) and law (e.g. national laws and guidelines). 
 
Noteworthy, the choice to investigate certain aspects of decision making in research from a 
linguistic perspective among AD patients, should be considered as a complement, not a 
supplement, to previous evaluations of MDC. Yet, multidisciplinary aspects and concerns are 
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intercepting the linguistic perspective of the thesis and are concisely to some extent discussed 
in the light of the results. 
 
Possible scientific uncertainties such as for example definition of critical key words like MDC, 
inclusion criteria of groups and possible methodological concerns of both the qualitative 
semantic analysis as well as the test design and results will be addressed even more distinctly 
in the two papers still in progress (study IV and V). Yet, methodological choices such as 
participants, measurements, analyses and results of the five studies will be brought up and 
discussed in the following sections. Finally, future implications and conclusions will be 
summed up. 
4.1.2 Participants 
All participants were given both written and oral information about the research project. It was 
ensured that all patients had been diagnosed (during the past 12 months) with either AD or MCI 
at the Memory clinical at Karolinska university hospital before being recruited. By including 
patients with mild to moderate dementia (MMSE: AD>20) and those with a mild cognitive 
impairment (MCI) (MMSE: MCI>25) but no dementia, we hoped to capture subtle diversity 
between groups. Another option may have been to include a larger group of AD patients in 
place of the MCI group, but in so doing we would have missed the opportunity to compare 
subtle changes in MDC, cognition and linguistic functions, between the two groups of patients. 
Another reason to include MCI patients was that they represent a group of subjects with 
impaired cognitive function, at risk of progressing to AD. 
 
The overall ambition of both data collections was to recruit approximately 20 participants in 
each group. In the first data collection we included in sum 79 participants (AD, n=20; MCI, 
n=22; and HC, n=37) and in the second data collection we included 55 participants (AD, n = 
21, MCI, n = 17 and HC, n = 17) to serve the purpose of current version of study V. In study II 
and III, five participants were excluded (one MCI and four HC) from data collection I, in order 
to match the groups even better in terms of demographic factors (age and education). Study IV 
was a qualitative report (semantic analysis) of different verbal utterances (participants 
responses from the standardized interview), and not designed to include a large number of 
participants.  
 
One inclusion criterion was overall cognitive function measured by the patients clinical score 
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on MMSE, chosen for reasons of convenience as it this score was reported in a standardised 
manner within the clinical examinations of all patients (in comparison to for example MoCA, 
which at the time had not been examined in all patients at the memory clinic). However, MoCA 
served the purpose to measure cognitive severity in data collection II (study V). It may possible 
have been beneficial to instead include both MMSE and MoCA to measure overall cognitive 
severity in both data collections, as the two tests differ in some respect – for example MoCA 
covers more spatial exercises in comparison to MMSE.  
 
The inclusion criteria for the healthy elderly subjects (HC) were age (>55 years), Swedish as a 
native language and no dyslexia or hearing/visual impairments (glasses and/or hearing aids was 
accepted) that could negatively affect their test performance. These criteria were important 
since all studies were based on the ability to read and comprehend the Swedish language.  
 
Approximately one third of all patients who matched the inclusion criteria accepted to 
participate. Reasons for not participating were not formally registered. Study III revealed an 
overall surprisingly high willingness to participate in the hypothetical clinical trials as 
approximately 90% of all participants expressed that they were willing to participate in the low-
risk trial, and approximately 40% were willing to participate in the high-risk trial (which was 
written to exaggerate side-effects beyond what would be accepted by an ethical committee for 
this type of treatment). To examine decisional capacity and attitudes toward research within 
and between groups - which already had a presumed average positive attitude on average toward 
research participation since they had volunteered to participate in current experimental research 
project - must be considered when interpreting the results in each study (especially study III). 
It is also important to consider that presumable other factors, besides group affiliation or 
cognitive and language impairment, may affect the results of the studies. For example, current 
emotional status, family situation, general knowledge of research and medical terms and 
previous experiences were not considered as part of the studies but could have had some impact 
on how the participants performed in the assessments of MDC by LIMD (study I) and KIMB 
(study V) and on how they reasoned and made decisions (studies III and IV). Additionally, it 
must be considered if the patient has interpreted the given information accurately. Finally, in 
practice some individuals may have difficulties to verbally express their thoughts and choices, 
without having an affected decisional capacity. These individuals may instead use other ways 
to communicate such as written communication, sign language or augmentative and alternative 
communication. Groups of individuals dependent communication other than verbal, were 
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however not included in any of the data collections. Hence, alternative ways of reasoning and 
communicating a choice was not evaluated in either of the studies but would be interesting to 
explore in a future study. 
 
The results in studies I-V could to some extent be generalized into other neurodegenerative 
diseases with compromised cognitive functions, but this hypothesis need to be examined 
systematically in a future study before any conclusions can be drawn. Impaired ability to make 
a reasonable decision could possibly be a result of an inability or unwillingness to actually 
"bother" rather than due to a reduced cognitive function. I imagine this could for example be 
the case for patients with depression or frontal injuries.  
 
It should be noted that, although the groups differ in diagnostic classification and significantly 
differ in terms of cognitive and linguistic measurements, a wide range of scores within groups 
was noted concerning for example measurements of general cognitive level (by MMSE or 
MoCA). Moreover, it is likely that other causes differ to some extent between the individuals 
in each group, such as emotional status and sleep disorders (which were not covered by the 
inclusion or exclusion criteria), which could affect the results of the studies. 
 
LIMD and KIMB were validated in a Swedish population with Swedish as native language, 
which lessens their usability in practice. Assessment of MDC in non-native speaking Swedish 
individuals entails further complexity to the field. Insufficient Swedish language capacity must 
not be valid reason for questioning decision-making capacity, but rather give cause to adapt the 
current situation (i.e. interpreter or language adapted information). 
 
Finally, all healthy adults are presumed to have sufficient decisional capacity, meaning they 
have the right to make their own decisions autonomously. Hence, age itself does not imply 
diminished decisional capacity, but age-related diseases such as dementia show a high 
correlation with reduced MDC. Along with an elderly population, society faces medical, ethical 
and health literacy challenges in dealing with age-related diseases such as dementia.  
4.1.3 Material and Assessments 
The cognitive and linguistic tests in study II were chosen on the basis of what tests that are 
routinely conducted in the clinical investigations by neuropsychologists and/or speech and 
language pathologists. The test battery (in total 14 tests, 27 measurements), was composed to 
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cover essential overall cognitive and linguistic functions by valid instruments and to match the 
clinical assessments. The categorisation of the tests by their measured capacities (overall 
cognitive function, language production, language comprehension, reading capacity, memory, 
spatial ability, executive function, attention and cognitive speed) presented in study II was a 
theoretical construction within the research project. It may be reasonable to discuss whether it 
was justifiable to include such a comprehensive test battery within the data collection I. It is 
possible that the participants may have found the high number of tasks challenging and may 
not have been performing consistently to the best of their abilities for the duration of 3-4 hours. 
However, it must firstly be mentioned that all participants were offered several pauses and 
coffee breaks throughout the test procedure, although it is still reasonable to imagine that their 
mental energy decreased after some time. Secondly, all tests were conducted in the same order, 
which at least partly enabled a comparison of results between groups (study II).  
 
Study IV contributes with an additional qualitative perspective, by analysing the responses by 
a detailed descriptive approach; a strength to the PhD-project. The semantic analysis of the 
utterances reported in study IV may be used for continued theorisation on how to evaluate the 
reasoning during a decision-making procedure.  
 
Finally, it should be emphasized that the methodology sections and results presented in study IV 
and V are work in progress and only selected parts from the papers are reported and discussed in 
the current thesis. The methodological choices, results and conclusions will to some extent be 
adjusted and discussed further out in revised versions of the papers.  
4.1.4 Statistics 
Correlations between groups, demographics and measurement scores were analysed by Pearson 
correlations (studies I-III and V). The literal terms high and strong versus low and weak were 
used to describe the output of the analyses. The correlations have sometimes also been 
described as “associations”. The statistical analyses were based upon parametric tests 
(Pearson’s correlation coefficient and ANOVA), which is considered powerful. However, as 
our sample sizes in each group were rather small and the choice of tests often depends on 
whether the mean or median more accurately represents the centre of our data’s distribution it 
may be argued that non-parametric tests would have been an appropriate choice. To “check” 
the credibility of previously published results, analyses of correlations have currently been re-
calculated by non-parametric tests (Spearman and Kruskal-Wallis, one-way non-parametric 
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ANOVA). The re-calculation showed results overall in consistency with previously published 
results. This means that no significant differences of relevance were found to report between 
the output of parametric and non-parametric analyses.  
4.2 THE LINGUISTIC APPROACH 
Speech and language pathologist are well trained to assess and analyse language and 
communication functions using numerous of tools and methodological procedures. Exploring 
different perspectives of language in the light of MDC evaluation, as done in current PhD-
project, is an innovative research approach, but perhaps also a future challenge for the discipline 
of speech and language pathology to exercise further out, in both clinical and research settings. 
Also, some previous studies raised from other scientific fields have indicated the significance 
of verbal knowledge in the MDC process, which are of great inspiration to current research.  
 
The linguistic approach in the five studies is summed as followed: 
I. Use of linguistic features (e.g. semantics and pragmatics) in the scoring protocol of 
MDC by the Swedish linguistic instrument of medical decision-making (LIMD), 
developed within the research project.  
II. Exploring how LIMD is correlated to different cognitive and linguistic components and 
single test (measuring e.g. speed, episodic memory, naming, word fluency, reading, 
comprehension, inference and repetition).  
III. Investigating what the participants actually are verbally responding (e.g. the meaning 
of their utterances) concerning acceptance to participate in hypothetical clinical trials 
and attitudes toward proxy and how they estimate risk and benefit. 
IV. Conducting a semantic analysis (identify signs of time, place and person) to explore the 
sense-making in verbal utterances concerning hypothetical contexts.  
V. Examining how a new brief reading task, KIMB-t (developed within the research 
project) can be useful to detect reduced capacity to give informed consent.  
 
The choice of prioritizing a linguistic aspect of decision-making did not intend to diminish other 
central impacts of decision-making capacity, rather contribute with an additional approach and 
high-lighting the complexity of the capacity.  
 
Note, in some of the methodological sections within the studies, cognition and language are 
presented in a parallel manner, e.g. “cognitive and linguistic tests” while for example the results 
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section in study II reports the linguistic function “verbal knowledge” as one of several cognitive 
components highly associated with MDC measured by LIMD. This might raise concerns about 
how to interpret the relationship between cognition and language. However, the thesis intention 
was to describe language as one of several functions within the wider overall term “cognition”, 
which indeed encompasses several mental processes such as thinking, attention, memory, 
learning, awareness, problem solving and decision-making. Hence, cognition is per this 
description linked to both language and decision-making, which is in coherence with previous 
findings (e.g. Okonkwo et al., 2007; Gerstenecker et al., 2015). Nevertheless, the general study 
of linguistics covers a number of elements, discussed by for example Johansson and Manninen 
(2012). They described the nature and properties in the human language and present different 
subfields of linguistics such as: morphology (study of internal structure of words and their 
parts), syntax (study of how words can be combined to form larger entities such as phrases and 
sentences), semantics (study of the meaning(s) of words, phrases and sentences) and pragmatics 
(study of how the speaker uses words, phrases and sentences). Studies I-V explore linguistic 
performance primarily within the sub-field of semantics such as investigating the meaning of 
linguistic elements like exploring how different linguistic features are usable to estimate MDC 
and analysis of sense-making in verbal utterances. In addition, other linguistic perspectives such 
as pragmatic and prosody were considered to some extent as part of the scoring protocol of 
LIMD.  
 
Furthermore, Johansson and Manninen (2012) discussed different perspectives regarding “the 
meaning of meaning” such as referential, mentalistic and different kinds of meaning from a 
linguistic approach. One literal key concept, among others, from the vignettes is “clinical trial”. 
The study of meaning from a referential approach would consider how the speaker talks about 
the concept such as “clinical trial” in an actual speak situation. If the study of the meaning of 
the concept “clinical trial” is approached from a psychological standpoint, questions may 
include how it is related to representations of mental images and how the speaker and listener 
interpret the world through these representations of the object. Further on, the meaning of 
“clinical trial” looked up in dictionary may be described something like “observations of actual 
patients in comparison to laboratory studies”. If we search instead for the encyclopaedic 
meaning, we will learn more about clinical trials in general as well as its associated terms. 
However, while semantics focuses on the literal meanings of words, phrases and sentences, 
which may be similar among speaker and listeners and in line with the definition given in a 
dictionary. meaning explained in a dictionary. Yet, individuals are for several reasons likely to 
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have different personal associations to the same concept or word. Some people may focus 
primarily on the risks associated to the concept of “clinical trials”, others on the benefits, and 
this may be based on the individual’s memory of previous experiences, current life situation 
and/or future plans, which presumable affect their verbal reasoning and decision. This 
assumption would be interesting to explore further in a study of semantics. The non-literal 
meaning of a concept, refers to the figurative language; how we use words, phrases and 
sentences to denote something different from their literal meaning, such as the use of metaphors, 
irony and hypothetical reasoning.  
 
In the present PhD-project, when (a) analysing the sense-making of speech (studies IV), (b) 
measuring the decisional capacity by ability the ability to comprehend, evaluate and 
communicate a choice (study I) and (c) analysing how groups estimated risks and benefits 
(study III), it was not primarily a matter of appreciating the participants’ ability to communicate 
the meaning of a word or concept such as “clinical trial". Their utterances were based upon 
hypothetical information and their reasoning was analysed and considered regarding their 
ability to capture this fictive situation (by LIMD; study I; semantic analysis; study IV and VAS; 
study III). Yet, their speech might have reflected their general knowledge and/or associations 
with “clinical trial” from previous experiences. 
 
The linguistic features used for scoring by LIMD are somewhat similar to those presented in 
the Modified Hierarchy of Evidence of Decision-making Capacity (Brauner and Merel, 2006) 
such as prosody (oral signs of continued attention e.g. “uh-uh”) and verbal elements 
(identification of single word answers and/or confirmatory language e.g. “yes, I think so” and 
“words signalling understanding of previous contribution”). This model by Brauner and Merel 
(2006) includes the decisional criteria “appreciation” (the ability to appreciate/”grasp” the given 
information and its consequences), which was not included as a separate standard in LIMD 
(rather embedded to some extent in the criteria of “evaluation and understanding”). The ability 
to appreciate the given information was explored further on in study III, in the sense of 
measuring self-estimated risk and benefit in various hypothetical trials by visual analogue scale 
(VAS; 0-100 mm).  
 
In a study by Tallberg (1999), the author emphasized the importance of recognising signs of 
misperception in patients with dementia. The individual’s self-image can be studied by 
analyzing how linguistic elements for referring to person, time and place are used in various 
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decisional situations. Furthermore, Brauner and Merel (2006) suggested that thoughtful actions 
by the interviewer, such as successfully repairing confusing language, can result in the 
participant being able to improve their decisional capability. The linguistic elements of person, 
time and place, were further explored by semantic analysis, as they were noted as absented or 
commonly used in some speech sequences of individuals in the AD and HC groups (study IV). 
Verbal reasoning may be incomprehensible if the elements of time, person and place in the 
reasoning are not used in a logical way, and difficulties in interpreting utterances may lead to 
assigning a patient impaired capacity of verbal reasoning and drawing the conclusion that the 
patient has insufficient MDC.  
 
The semantic analysis conducted in study IV was an analysis of the participants’ responses and 
not a result of the interaction between test leader and participant. One may discuss the actions 
of the test leader during the strict interview as part of LIMD, which had a strict standardised 
format (i.e. did not allow any additional interaction and / or conversation between the test leader 
and the participant). If the test leader had instead facilitated a somewhat freer conversation, it 
may have helped the respondent to better and more easily answer the given questions. 
Participants’ requests for verbal clarification, such as “what”, could in a free dialogue have been 
recognized and “picked up” by the researcher and responded to with clarification of the given 
information. Moreover, the analysis did not report on overall communication or analysis of non-
verbal language like eye-movement and gestures, which could have been captured by a video 
recorder and have contributed to additional central communicative elements in the analysis of 
patient’s sense-making. In sum, a linguistic perspective can provide valuable information about 
how and when different phenomena occur in speech and may also help to distinguish different 
pattern in terms of linguistic phenomena that may indicate an impaired ability to reason 
rationally.  
4.3 LIMD AND KIMB-T 
In order to understand the strengths and limitations regarding the test designs of LIMD and 
KIMB as well as to avoid unnecessary confusions it is important to define certain key words 
and concepts in the thesis. In the current thesis one key concept, among others can be identified 
as medical decision-making capacity, abbreviated in the different studies as MDC or MDMC. 
Each study targeted what the capacity actually was referred to by their objectives and 
descriptions in the methodology sections such as: “capacity to make decisions in medical 
contexts, based on text information concerning possible participating in hypothetical clinical 
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trials” (i.e. MDC for research settings). But, although this definition was well settled within the 
research project, it could perhaps have been defined more stringent throughout the total text of 
each study. For example, MDC/MDMC could in some cases, isolated from its overall context 
be misinterpreted as referring to “overall capacity” or “capacity to treatment”. Also, definitions 
of the capacity and standards from external references, could in some cases have been clarified 
yet more stringent. For example, in the introduction section of study I, the text was referring to 
legal standards (LS) for MDMC by Okonkwo et al, (2008), who examined the capacity by the 
Capacity to Consent to Treatment Instrument (CCTI, Marson et al., 1995a), which covers the 
four treatment consent standards: (S1) expressing choice, (S3) appreciation, (S4) reasoning, 
and (S5) understanding, as well as one experimental standard (S2) reasonable choice.  
 
It is a challenge to develop standardised, reliable and valid instruments for measuring MDC as 
the latter may be defined by various criteria and examined using different scientific approaches. 
The two instruments LIMD and KIMB-t, contribute an additional linguistic perspective to the 
field of MDC assessment. The tests show certain similarities, yet some differences in-between 
and in comparison, to other well recognized previously developed instruments. For instance, 
LIMD serves to assess certain linguistic features of MDC, while KIMB-t serves to detect 
possible reduced capacity for research participation, e.g. to give informed consent. No clear 
diagnostic “gold standard” or specific cut off values have been clearly settled to define 
insufficient decisional capacity, which is a key complication when developing valid and reliable 
new instruments to assess MDC. The validity of LIMD, as well as some preliminary results of 
KIMB-t score, are discussed in following sections. 
4.3.1 Diagnostic validity 
The diagnostic validity of LIMD and KIMB-t was investigated by comparing the test results 
among the three groups with varying in degrees of cognitive function (AD, MC and HC). The 
analyses were based on two separate data collections (carried out on similar groups but with 
different individuals). Study I reported strong diagnostic validity of LIMD, based on significant 
group differences of LIMD score (p<.001) and post-hoc t-test analyses of pair-wise group 
differences showed that the LIMD score significantly separated the three groups respectively 
(p<.001). Study V showed that KIMB-t had diagnostic validity only to some degree, as KIMB-
t did not capture the subtle decline in MDC between patients with varied cognitive function 
(AD and MCI). A significant group difference (p < 0.05) and Tukey’s post-hoc t-test revealed 
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that the KIMB-t score was significantly higher for the HC group than the AD group (p < 0.05) 
while no significant difference was found between HC and MCI nor between AD and MCI.  
4.3.1.1 General concerns 
The AD and MCI patients included in the studies were all diagnosed according to standardised 
diagnostic criteria at the same memory clinic, and there were no significant demographic 
differences among groups regarding age or educational level in any study. However, it is 
difficult to ensure the homogeneity of the groups concerning other aspects not considered such 
as emotional state. In addition, it is well recognised that a diagnosis in itself is rarely enough to 
determine decisional capacity. An individual with a cognitive impairment due to dementia may 
have insufficient capacity in relation to complex decisional contexts, but still sufficient capacity 
in certain medical settings, such as low-risk treatment decisions (Appelbaum & Grisso 1988). 
It is worth noting that LIMD was not intended to serve the purpose of categorising individuals 
as having sufficient or insufficient overall capacity, rather it sought to examine degree of MDC 
for research based on linguistic features. LIMD was also intended to serve as a research 
instrument to investigate possible cognitive and linguistic correlates to MDC by LIMD. KIMB-
t, on the other hand was designed for possible clinical use to detect individuals with reduced 
capacity to give informed consent (based on written information). These individuals could 
presumable need a more comprehensive assessment of MDC and/or facilitating aids during the 
decisional procedure.  
4.3.2 Construct validity 
4.3.2.1 LIMD 
The construct validity of LIMD was explored with a fundamental and detailed scoring 
procedure (study I) of three criteria of MDC (comprehension, evaluation and intelligibility of 
choice). In addition, LIMD-total score was correlated with the results to overall cognitive 
components as well as single tests (study II).  
 
Study I showed high and significant correlations between LIMD and three criteria of decision-
making. The overall validity was approximately 80% defined as the degree of variance in LIMD 
accounted for by group in one-way (groups) ANOVA on LIMD. The LIMD-criteria were 
inspired by previously well-recognized consent standards (S) (derived from legal standards 
(LS) for competence): S1) expressing choice; S2) making a reasonable choice; S3) appreciating 
choice; S4) providing rational reasons for choice; and S5) understanding information relevant 
of a choice, which have been discussed and evaluated in several previous studies (e.g. 
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Appelbaum & Grisso, 1988; Marson et al., 1995; Okonkwo et al., 2008a) and discussed in the 
light of LIMD below: 
 
• Comprehension (how the responses correspond to the content of the vignettes, in line 
with S5: understanding information relevant of a choice). In order to understand the 
information required to answer the standardized LIMD questions, which were given 
orally, the participant needed to first comprehend the given information (the vignettes), 
which was given both orally and in written form. To master the task the participant 
needed fundamental abilities such as (a) receipt of information, likely depending on 
attention and receptive language skills) as well as (b) active consciousness and working 
memory (Palmer & Harmell, 2016). However, to ease the burden on the memory 
function, and to increase the chances that you actually measure the “right thing”, which 
in this case is the ability to understand and to simulate a real situation, the participant 
was allowed to keep the vignette text ahead and was invited to reread the text while 
answering the questions if needed. It is, not possible to exclude the impact of memory 
when assessing the dimension of understanding, although the linguistic aspect is central 
when it comes to genuine comprehension (beyond the mere ability to ”parrot” the words 
back to the examiner). Also, Amalraj, Starkweather, Nguyen and Naeim (2009) argue 
that preserved verbal knowledge and health literacy are core functions in true 
comprehension. 
 
• Evaluation (how utterances reveal the way subjects evaluate and weight the risks and 
benefits of participation, in line with S3: appreciating consequences of choice and S4; 
providing rational reasons for choice). Palmer and Harmell (2016) have suggested that 
the reasoning process involves the ability to envision and compare the potential 
consequences of various options. In order to answer the LIMD interview questions, the 
participant needed to reason about the content of the vignette in addtion to to 
comprehending the given hypotetical situation (vignettes). Also, in order to previse a 
future event, such as the potential risks involved in a clinical trial (whether real or 
hypothetical), the participant needed both sufficient working memory, and executive 
functions such as abstraction and planning (Grisso & Appelbaum, 1998). Making a 
reasonable choice, associated to appreciation was considered difficult to operationalize 
in a reliable manner. We preferred to merge appreciating and rational reasons into one 
overall criteria entitled “evaluation”. The choice to exclude appreciation from the 
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scoring protocol of LIMD was not an action to diminish its actual relevance in relation 
to the capacity. Appreciating and rational reasons were instead further explored by a 
different methodological approach in study III (self-estimation of risk and benefit by 
VAS, verbalized reasons to participate and attitudes toward proxy). 
 
• Intelligibility of choice (how decisive utterances are expressed and formulated, in line 
with S1, expressing a choice and the exprimental standard S2: making the reasonable 
choice). The ability to communicate a choice, was primarily examined by questions 8: 
“Would you choose to participate?” and 8.a: “Why would you participate?/What would 
be the reasons for you participatation?”. In order to answer these questions i.w. to come 
to a conclusion and give informed consent rather than randomly answering yes or no, 
the participant needed (a) certain degree of contextual comprehension, (b) ability to 
mentally process the information and (c) to finally communicate a choice, which within 
the LIMD assessment requires a sufficient expressive oral language function. However 
in real clinical settings the reasoning and decisions could, if needed, be communciated 
differently, i.e. sign language and/or alternative and augmentative communciation. 
Furthermore, executive function i.e. mental flexibility and poor inhibition are likely 
critical abilities when communicating different choices (regardless if it’s based on a real 
or hypothetical contexts). 
 
Study II reported strong association between LIMD score and several cognitive and linguistic 
tests measures which are commonly included in the clinical assessments by neuropsychologists 
and speech and language pathologists in a clinical investigation of cognitive function. The study 
reported that the results of four single, cognitive and linguistic measurements were significant 
strongly correlated to total LIMD score: (1) Reading Speed (Järpsten, 2002), measuring e.g. 
reading capacity, speed and comprehension; (2) RAVLT (Lezak et al., 2004; Schmidt, 1996), 
measuring e.g. verbal episodic memory; (3) Inference (BeSS; Laakso et al., 2000; Holmbro & 
Olsson, 2000), measuring e.g. ability to draw conclusions from given information, and (4) 
Sentence Repetition (BeSS; Laakso et al., 2000; Holmbro & Olsson, 2000), measuring e.g. 
verbal repetition. The single test that best could predict MDC by LIMD was Reading Speed 
(R=.77; p<.001), included in the “verbal component”. The result of study II supports the attempt 
of developing an instrument which captures linguistic characteristics of medical decision-
making. 
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Sufficient verbal ability is essential in the process of medical decision-making in order to 
comprehend spoken and/or written language, to communicate decisions and to do so in an 
intelligible way. The impact of verbal ability e.g. verbal retrieval to the decisional capacity has 
been showed also in previous studies (e.g. Marson et al. 1995 and Gurrera et al., 2006). 
However, subtle changes of the language function and its correlation to decisional capacity in 
different contexts should preferable be further specified. For example, sufficient reading 
capacity is crucial in the decision-making process if the context is text-based (but its need yet 
to be explored how it is applicable in different texts with varied complexity as well as when the 
information is given with or without orally support). Information provided in order to give 
informed consent may well be written in academic language and include unfamiliar medical 
terminology. Eltorai et al. (2015) investigated readability in certain consent forms and found 
that in order to read (and comprehend) such a text, the reader likely needs to master a higher 
level of education. They suggest that adjustments to the readability of consent forms could 
enhance patient comprehension during the decision-making process, a finding in line with the 
previously stated importance of health literacy (e.g. Nutbeam, 2008). However, it may be 
suggested that the strong correlation between linguistic capacity and MDC as measured with 
LIMD could be to the fact that MDC in research contexts is parse a critical linguistic process. 
In any case, one can conclude with relative certainty that several aspects of verbal ability are 
crucial for medical decision-making in research settings. Finally, it must be noted that the 
construction validity of LIMD and possible predictors of MDC as measured by LIMD, was 
restricted to the choice of criteria, standardised questions and scoring protocol as well as which 
cognitive and linguistic tests were included in the correlation analysis of study II (as well as 
how these tests were subcategorized into different cognitive components). 
4.3.2.2 KIMB-t 
When investigating if the tests actually catches what they were aimed to capture it is crucial to 
define what they are valid to measure. For example, KIMB-t is not constructed to measure 
universal decision-making, but rather to detect reduced capacity to give informed consent (by 
assessing the ability to read quickly with sustained understanding and ability to draw 
conclusions from written information.) The construct validity of KIMB-t was explored in Study 
V by correlating the task to different cognitive tests with assumed high correlation to MDC by 
LIMD (according to study II). It would naturally have been beneficial to also include a 
comprehensive test battery (including LIMD) also in study V. However, the four tests were chosen 
as a golden middle way between the wish to investigate the construct validity as thoroughly as 
possible, and the wish to moderate the study’s demands on the subjects’ time and effort. KIMB-t is 
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neither based upon the well-recognised vignette method, nor designed to measure decision capacity 
tailored to the current decisional situation or overall capacity. The construction of KIMB-t was 
filtered down to assess certain linguistic functions (reading speed and reading comprehension) with 
presumable high association to MDC assessed by LIMD. The validity of KIMB-t was based on the 
fact that the task correlated significantly (p < 0.05) to the four cognitive tests previously associated 
with MDC as measured by LIMD. As expected, it did not correlate significantly to the task (word 
sequence production (Östberg et al., 2008) with assumed no association with MDC.  
4.3.2.3 General concerns 
It is widely recognised that medical decision-making is a complex process, associated with 
several cognitive and linguistic abilities and may fluctuate and change in time for several 
reasons, not limited to cognitive function (e.g. emotional or medical condition). Gurrera et al. 
(2014), indicated that, when evaluating decision-making, it may be important to attend not only 
to the patient’s level of cognitive function but also to intra-individual in performance on 
neurocognitive tests. The complexity of MDC is such that neither LIMD nor KIMB can be used 
to determine MDC as the capacity may vary and is associated to multiple factors. A possible 
new title in a revised version of study V could be, for example: “A brief Swedish reading tool 
to detect reduced capability to give informed consent in dementia”. 
4.3.3 Ecological validity 
Ecological validity refers to whether chosen methods, materials and settings approximate the 
relevant real-world situation and/or environment (but must not necessarily be equal to the 
overall validity of a study). The test design of LIMD and KIMB were based upon texts which 
imitated a decisional-making situation, but presented in a hypothetical manner, describing 
hypothetical clinical trials. A notable difference between the texts of LIMD and KIMB, is that 
the fictive patient described in LIMD is referred to as second person, “Imagine that you…”, 
which might be confusing for patients with cognitive impairment while the fictive subject in 
the KIMB text is described in third person as the unisex subject “Kim”. It is not well-
investigated what impact such an innovative test design, like KIMB might have on the overall 
ecological validity of the task, in comparison to other. 
 
Both LIMD and KIMB include tasks which present written fictive information (the information 
is also given orally within LIMD). The tests do not genuinely involve the patient’s perspective, 
i.e. in terms of "me, myself here and now", but rather require consideration of: “me or another 
person at another place and time”. It may be argued that this hypothetical approach could have 
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a negative influence on the ecological validity, and it is therefore necessary for the 
researcher/clinician to consider the possible limitations of the conclusions drawn from the 
results. Palmer and Harmell (2016) note that a disadvantage of the use of vignette-instruments; 
is that they primarily serve to assess overall capacity, rather than to define whether or not the 
patient can give consent to a suggested specific medical issue. Hence, it may be argued that the 
vignette method is more suitable for research settings, for example to evaluate the different 
factors affecting the capacity (rather than the patients actual and overall decisional capacity, 
generalisable to any clinical setting). However, numerous of valid instruments which assess 
healthcare decision making are based upon the vignette method (e.g. Grisso et al., 1997; Marson 
et al. 1995a; Moye et al., 2008). 
4.3.4 Usefulness 
LIMD is considered a valid and reliable research instrument to assess linguistic features of 
medical decision-making in research settings and is suitable to capture subtle changes among 
groups. Yet, the test is not suitable for clinical practice, which diminish its usefulness. KIMB 
on the other hand is applicable to be used in clinical settings e.g. when patients’ capacity for 
consent to clinical research based on written information needs to be briefly estimated in a 
standardized and objective manner. Yet, it seems difficult to capture subtle changes among 
groups by KIMB. Neither of the two tools are valid to assess universal medical decision-making 
capacity or capacity based on oral information. 
4.4 ETHICAL ISSUES  
Dementia is a growing and serious challenge in health care and society. Research is necessary 
and important for achieving success in curing neurodegenerative diseases such as AD. In order 
to eventually achieve the goal of curing diseases, highly specialized research and voluntary 
participation in clinical trials are required, but this must not happen at the expense of the 
individual's interests. It is well known that research involving patients with impaired cognitive 
function may imply ethical challenges concerning for example how to best protect the 
individual's interest and autonomy without compromising medical safety. The overall objective 
of the five studies concerns the challenge to evaluate and analyse medical decision-making from 
a linguistic perspective i.e. the objective of the thesis was not to explore and discuss MDC from 
the discipline of medical ethics. Yet, some ethical concerns associated to the PhD-project are 
emphasised and problematized in the thesis.  
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Are AD patients capable of giving informed consent? Perhaps, perhaps not: perhaps in some 
contexts, but not in others. Ethical issues associated with the results of the studies can be 
discussed from two major perspectives: (1) patient’s perspective (e.g. how to make and 
communicate a genuine and well-thought-out and independent decision about one’s own 
(hypothetical) future and considerations and thought associated to the choice of a future proxy) 
(2) clinician’s perspective (e.g. how to make a valid interpretation of a patient’s decision-
making capacity/ to estimate consent capacity).  
 
Sullivan (2008) has reported a general lack of dementia awareness amongst the general 
population, despite the fact that many people know at least one person with dementia. 
Insufficient public knowledge about dementia may result in an absence of reflection by friends 
and family members on the consequences of reduced MDC for patient’s autonomy. Excluding 
individuals with dementia from the decision-making process may lead to increased levels of 
depression and frustration for the patients (Smebye et al., 2012). This accords a particular 
responsibility to include the patient as much as possible in all decisions concerning her/his own 
situation. Yet, it is a challenge to ensure that patients with presumable reduced MDC have 
understood the actual message of assigned information. According to the Declaration of 
Helsinki (World Medical Association, Declaration of Helsinki, 2013) it is critical that the 
specific information needed for potential subjects should be adapted during the informed 
consent process. Hug and Johansson (2017) emphasize that the researcher should aim to 
improve the understanding for the research candidate and stress that it is critical to consider 
what information should be obtained in addition to how it is provided. For ethical reasons, the 
inclusion criteria of the data collections (I and II) did not include patients with severe dementia, 
as they would have had high risk of critically reduced MDC. It was taken into account that some 
of the participants may have had weak health literacy and possible, to some extent reduced 
decisional capacity regarding the decision whether to participate in the study. However, 
participation was not associated with any obvious risks for the participant and the studies were 
accepted by the ethical vetting board.  
 
Furthermore, according to the results reported by study III, the acceptance of proxy is different 
depending on the potential risk following participation in the hypothetical clinical trial. 
However, it is difficult to in an objective manner take into account presumed risk (as this may 
be a subjective matter) when applying for a proxy, which could be considered an ethical issue. 
In reality, if a proxy maker is considered necessary and entrusted to act deputy in medical 
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matters, such as proxy consent to clinical trials, it is the case regardless of degree of assumed 
risk and benefit of the study. Another issue concerns the fact that decisional capacity may be 
investigated and discussed only in situations when the patient refuses the recommended medical 
action, if at all. Also, if a patient with questionable (but not obviously impaired) MDC makes a 
deviant decision contrary to the clinician’s professional suggestion, the clinician may query the 
patients’ decisional capacity rather than simply accepting the decision. Strong autonomy and 
self-determination are based on the person's capacity to be responsible for her / his own actions 
and requires that the choices are both voluntary and rational. Hence, to truly respect a patient, 
one must preferably know which decision the patient would have made before her / his 
decisional capacity was reduced. Defining the criteria for MDC and using instruments that 
assess this ability requires a high level of ethical responsibility on the part of the clinician or 
researcher. It is important not to violate the rights of those who can actually make their own 
decisions in attempt to protect those with reduced decision-making capacity. It must be noted 
that an assessment of decision-making capacity by any scoring protocol is the assessor's own 
interpretation of the test used. It is of ethical importance to always maintain the human value 
as a central concept. No simple solution nor an absolute truth exists of when and how to estimate 
MDC nor how to know if the patients informed consent is really based on true health literacy. 
Finally, the risk of abuse as well as misinterpretation of the result must be taken into account 
when developing new measurement tools. For example, LIMD should primarily be used for 
research purposes and KIMB-t ought to be used to identifying patients in need of further 
examination or support in order to be able to exercise their autonomy. The studies investigated 
linguistic aspects of MDC in groups with variable cognitive function. Consequently, the 
participants were assumed to have different degree of decision-making capacity. Johansson 
(2017) discussed some key principles that ought to protect individuals who have insufficient 
decisional capacity. One issue to consider in current PhD-project is whether it was in 
accordance with good ethical practice to perform data collections (I and II). The data collections 
can be acceptable according to the principle of risk minimisation and insignificant risk as the 
participants in our research project were not exposed to any intervention or analysis that 
deliberately exposed them to any obvious risk of being harmed physically or psychologically. 
It could perhaps be argued that the patients may have been exposed to mental stress (i.e. being 
subject to a number of tests) that may have been experienced as disappointing or stressful. For 
this reason, the participants were (a) clearly informed that it was voluntary and that they were 
allowed to exit the research project at any time and (b) welcomed to pause the test procedure 
and take a coffee break or talk a walk between the tests. Furthermore, we strived for that the 
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overall research project was in accordance with the principle of utilitarianism, and that the 
principles of necessity and population were met, since the studies aimed to contribute with 
exploratory results to the field of decision-making and in addition benefit the fragile group of 
elderly with possible reduced decisional capacity. Finally, for ethical reasons, the entire 
transcriptions showing of the total amount of verbal responses from each participant were not 
reported in any study, which may otherwise have risked identification. In sum, we believe that 
the overall study design and objectives conformed to ethical standards for research. 
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5 CONCLUSIONS 
In comparison with healthy individuals and those with MCI, individuals with mild AD showed 
reduced MDC, measured as the capacity to give informed consent for research participation by 
LIMD. The total LIMD score, including the criteria; comprehension, evaluation and 
intelligibility, were highly associated to the component of overall verbal knowledge, counting 
the single measurements of Reading speed and Inference, as well as the components of episodic 
memory, cognitive speed and working memory. In addition, patients, already with mild AD 
seemed to have reduced capacity to estimate possible risks associated with participation to a 
clinical trial, as well as having difficulties to reason and communicate a choice in a clear and 
logical manner. 
 
The results indicate that a linguistic approach of MDC among patients with AD, contributes not 
only to an additional analysis of the capacity, but also to a better understanding in the 
communication with patients during the decision-making process. Hence, evaluating different 
aspects associated to medical decision-making from a linguistic perspective in AD and other 
groups with impaired cognitive function, complements the research field, which hopefully and 
eventually will benefit the patients.  
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6 FUTURE DIRECTIONS 
A longitudinal study of MDC by LIMD on groups of patients with AD and MCI would be an 
interesting follow-on from the present study, as the patients’ decisional capacity is at risk of 
becoming impaired over time due to the cognitive and linguistic effects of the disease, neither 
is it well-recognized if and how patients’ estimations of risk and benefit, and their decisions to 
participate in for example high-risk trials would change over time and how the sense-making 
of their verbal reasoning may differ. Additionally, several international instruments to assess 
medical decision-making show good reliability and validity. A future suggestion would be to 
translate and validate a previously established instrument that measures MDC for research 
participation into Swedish and compare its results to LIMD score among different groups, for 
example HC and patients with mild and severe AD, MCI and FTD.  
 
Furthermore, it would be of interest to explore how estimation of MDC could be conducted as 
part of a standardized clinical investigation, as well as how such an approach could possible 
benefit the patient in both research and clinical settings. Finally, it would be valuable to 
investigate how to communicate, in best possible ethical manner, with dementia patients during 
their medical decision-making process i.e. standardized dialogue concerning decision-making 
abilities such as comprehension, estimation of risk and benefits, willingness to participate and 
choice of proxy, during different stages of their diseases. 
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